BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, Del Ninno E, Morabito A, Colombo M. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology. 2006;43:1303-1310. [PMID: 16729298 DOI: 10.1002/hep.21176] [Cited by in Crossref: 396] [Cited by in F6Publishing: 343] [Article Influence: 26.4] [Reference Citation Analysis]
Number Citing Articles
1 Jacobson IM, Lim JK, Fried MW. American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection. Gastroenterology. 2017;152:1578-1587. [PMID: 28344022 DOI: 10.1053/j.gastro.2017.03.018] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 12.3] [Reference Citation Analysis]
2 Pan Y, Qin T, Jiang H, Wu S, Gu J. Detection of hepatitis C virus in serum and peripheral blood mononuclear cells by two reverse transcription polymerase chain reactions: . Chinese Medical Journal 2007;120:431-3. [DOI: 10.1097/00029330-200703010-00017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Ioannou GN, Splan MF, Weiss NS, McDonald GB, Beretta L, Lee SP. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2007; 5: 938-945, 945.e1-945. e4. [PMID: 17509946 DOI: 10.1016/j.cgh.2007.02.039] [Cited by in Crossref: 140] [Cited by in F6Publishing: 122] [Article Influence: 10.0] [Reference Citation Analysis]
4 Wu CC, Tseng CW, Tseng KC, Chen YC, Wu TW, Chang SY, Chang YJ, Chao YC, Hsu CS. Radiofrequency ablation versus surgical resection for the treatment of solitary hepatocellular carcinoma 2 cm or smaller: A cohort study in Taiwan. J Formos Med Assoc 2021;120:1249-58. [PMID: 33288401 DOI: 10.1016/j.jfma.2020.11.010] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Tovo CV, de Mattos AA, de Almeida PR. Chronic hepatitis C genotype 1 virus: who should wait for treatment? World J Gastroenterol. 2014;20:2867-2875. [PMID: 24659878 DOI: 10.3748/wjg.v20.i11.2867] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
6 Watanabe T, Sakamoto N, Nakagawa M, Kakinuma S, Itsui Y, Nishimura-Sakurai Y, Ueyama M, Funaoka Y, Kitazume A, Nitta S, Kiyohashi K, Murakawa M, Azuma S, Tsuchiya K, Oooka S, Watanabe M. Inhibitory effect of a triterpenoid compound, with or without alpha interferon, on hepatitis C virus infection. Antimicrob Agents Chemother 2011;55:2537-45. [PMID: 21444704 DOI: 10.1128/AAC.01780-10] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
7 Shakado S, Sakisaka S, Chayama K, Okanoue T, Toyoda J, Izumi N, Matsumoto A, Takehara T, Ido A, Hiasa Y, Yoshioka K, Nomura H, Ueno Y, Seike M, Kumada H. Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development. World J Hepatol 2015;7:2757-64. [PMID: 26644819 DOI: 10.4254/wjh.v7.i27.2757] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
8 O'Leary JG, Davis GL. Hepatitis C virus replication and potential targets for direct-acting agents. Therap Adv Gastroenterol 2010;3:43-53. [PMID: 21180589 DOI: 10.1177/1756283X09353353] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Garg G, Dixit VK, Shukla SK, Singh SK, Sachan S, Tiwari A, Yadav VK, Yadav DP. Impact of Direct Acting Antiviral Drugs in Treatment Naïve HCV Cirrhosis on Fibrosis and Severity of Liver Disease: A Real Life Experience from a Tertiary Care Center of North India. J Clin Exp Hepatol 2018;8:241-9. [PMID: 30302040 DOI: 10.1016/j.jceh.2017.11.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
10 Velosa J, Serejo F, Marinho R, Nunes J, Glória H. Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis. Dig Dis Sci. 2011;56:1853-1861. [PMID: 21374066 DOI: 10.1007/s10620-011-1621-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
11 Huang Y, de Boer WB, Adams LA, MacQuillan G, Bulsara MK, Jeffrey GP. Clinical outcomes of chronic hepatitis C patients related to baseline liver fibrosis stage: a hospital-based linkage study. Intern Med J 2015;45:48-54. [PMID: 25371273 DOI: 10.1111/imj.12626] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
12 Hyde AJ, Nassabein R, AlShareef A, Armstrong D, Babak S, Berry S, Bossé D, Chen E, Colwell B, Essery C, Goel R, Goodwin R, Gray S, Hammad N, Jeyakuymar A, Jonker D, Karanicolas P, Lamond N, Letourneau R, Michael J, Patil N, Powell E, Ramjeesingh R, Saliba W, Singh R, Snow S, Stuckless T, Tadros S, Tehfé M, Thana M, Thirlwell M, Vickers M, Virik K, Welch S, Asmis T. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2018. Curr Oncol 2019;26:e665-81. [PMID: 31708660 DOI: 10.3747/co.26.5193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Jacobson IM, Davis GL, El-Serag H, Negro F, Trépo C. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2010;8:924-33; quiz e117. [PMID: 20713178 DOI: 10.1016/j.cgh.2010.06.032] [Cited by in Crossref: 82] [Cited by in F6Publishing: 71] [Article Influence: 7.5] [Reference Citation Analysis]
14 O’Leary JG, Lepe R, Davis GL. Indications for liver transplantation. Gastroenterology. 2008;134:1764-1776. [PMID: 18471553 DOI: 10.1053/j.gastro.2008.02.028] [Cited by in Crossref: 120] [Cited by in F6Publishing: 82] [Article Influence: 9.2] [Reference Citation Analysis]
15 Linas BP, Barter DM, Leff JA, DiLorenzo M, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Kim AY, Freedberg KA. The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients. AIDS 2014;28:365-76. [PMID: 24670522 DOI: 10.1097/QAD.0000000000000093] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
16 Pho MT, Jensen DM, Meltzer DO, Kim AY, Linas BP. Clinical impact of treatment timing for chronic hepatitis C infection: a decision model. J Viral Hepat 2015;22:630-8. [PMID: 26135026 DOI: 10.1111/jvh.12412] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
17 Chang KC, Ye YH, Wu CK, Lin MT, Tsai MC, Tseng PL, Hu TH. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy. J Formos Med Assoc. 2018;117:1011-1018. [PMID: 29254684 DOI: 10.1016/j.jfma.2017.11.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
18 López-Martínez R, Arias-García A, Rodríguez-Algarra F, Castellote-Bellés L, Rando-Segura A, Tarraso G, Vargas-Accarino E, Montserrat-Lloan I, Blanco-Grau A, Caballero-Garralda A, Ferrer-Costa R, Pumarola-Sunye T, Buti-Ferret M, Esteban-Mur R, Quer J, Casis-Saez E, Rodríguez-Frías F. Significant Improvement in Diagnosis of Hepatitis C Virus Infection by a One-Step Strategy in a Central Laboratory: an Optimal Tool for Hepatitis C Elimination? J Clin Microbiol 2019;58:e01815-19. [PMID: 31694971 DOI: 10.1128/JCM.01815-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
19 Mokrane FZ, Lu L, Vavasseur A, Otal P, Peron JM, Luk L, Yang H, Ammari S, Saenger Y, Rousseau H, Zhao B, Schwartz LH, Dercle L. Radiomics machine-learning signature for diagnosis of hepatocellular carcinoma in cirrhotic patients with indeterminate liver nodules. Eur Radiol. 2020;30:558-570. [PMID: 31444598 DOI: 10.1007/s00330-019-06347-w] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 15.5] [Reference Citation Analysis]
20 Bruno S, Crosignani A, Facciotto C, Rossi S, Roffi L, Redaelli A, de Franchis R, Almasio PL, Maisonneuve P. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology. 2010;51:2069-2076. [PMID: 20196120 DOI: 10.1002/hep.23528] [Cited by in Crossref: 148] [Cited by in F6Publishing: 121] [Article Influence: 13.5] [Reference Citation Analysis]
21 Kim HC, Suk KT, Kim DJ, Yoon JH, Kim YS, Baik GH, Kim JB, Kim CH, Sung H, Choi JY, Han KH, Park SH. Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma. World J Gastroenterol 2014;20:745-54. [PMID: 24574748 DOI: 10.3748/wjg.v20.i3.745] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
22 Dufour JF. Modern hepatomancy. Gastroenterology. 2013;144:876-878. [PMID: 23528666 DOI: 10.1053/j.gastro.2013.03.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
23 Caviglia GP, Abate ML, Rolle E, Carucci P, Armandi A, Rosso C, Olivero A, Ribaldone DG, Tandoi F, Saracco GM, Ciancio A, Bugianesi E, Gaia S. The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma. Biology (Basel) 2021;10:215. [PMID: 33799723 DOI: 10.3390/biology10030215] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Gomez EV, Bertot LC, Rodriguez YS, Gonzalez AT, Perez YM, Garcia AY. The natural history of HCV-related cirrhosis and its temporal progression across the different clinical stages. Hepatol Int 2014;8:527-39. [DOI: 10.1007/s12072-014-9565-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
25 Tong MJ, Theodoro CF, Salvo RT. Late development of hepatocellular carcinoma after viral clearance in patients with chronic hepatitis C: A need for continual surveillance: Late onset of HCC after HCV clearance. Journal of Digestive Diseases 2018;19:411-20. [DOI: 10.1111/1751-2980.12615] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
26 Poordad F, Castro RE, Asatryan A, Aguilar H, Cacoub P, Dieterich D, Marinho RT, Carvalho A, Siddique A, Hu YB, Charafeddine M, Bondin M, Khan N, Cohen DE, Felizarta F. Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials. J Viral Hepat 2020;27:497-504. [PMID: 31954087 DOI: 10.1111/jvh.13261] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
27 Kulik LM. Advancements in hepatocellular carcinoma: . Current Opinion in Gastroenterology 2007;23:268-74. [DOI: 10.1097/mog.0b013e3280ec5113] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
28 Coffin PO, Scott JD, Golden MR, Sullivan SD. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis. 2012;54:1259-1271. [PMID: 22412061 DOI: 10.1093/cid/cis011] [Cited by in Crossref: 75] [Cited by in F6Publishing: 82] [Article Influence: 8.3] [Reference Citation Analysis]
29 Amiel C. [Cancer and HIV: understand and act]. Med Mal Infect 2008;38:625-41. [PMID: 19028035 DOI: 10.1016/j.medmal.2008.10.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
30 Mar J, Martínez-Baz I, Ibarrondo O, Juanbeltz R, San Miguel R, Casado I, O'Leary A, Castilla J. Survival and clinical events related to end-stage liver disease associated with HCV prior to the era of all oral direct-acting antiviral treatments. Expert Rev Gastroenterol Hepatol 2019;13:699-708. [PMID: 28946785 DOI: 10.1080/17474124.2017.1383155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
31 Hassany SM, Hassan W, Abo-Alam H, Khalaf M, Nafeh AM, Nasr-Eldin E, Mostafa EF. Direct-Acting Antiviral Drugs and Occurrence of Hepatocellular Carcinoma: Unjust or Oppressed. Infect Drug Resist 2020;13:1873-80. [PMID: 32606836 DOI: 10.2147/IDR.S241948] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Fujimoto K, Sawabe M, Sasaki M, Kino K, Arai T. Undiagnosed cirrhosis occurs frequently in the elderly and requires periodic follow ups and medical treatments. Geriatr Gerontol Int. 2008;8:198-203. [PMID: 18822004 DOI: 10.1111/j.1447-0594.2008.00470.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
33 Abdelaty LN, Elnaggar AA, Said AA, Hussein RRS. Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients. Curr Drug Saf 2020;15:53-60. [PMID: 31573893 DOI: 10.2174/1574886314666191001151314] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Elbasha EH, Robertson MN, Nwankwo C. The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States. Aliment Pharmacol Ther 2017;45:455-67. [PMID: 27910116 DOI: 10.1111/apt.13882] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
35 Lawitz E, Flisiak R, Abunimeh M, Sise ME, Park JY, Kaskas M, Bruchfeld A, Wörns MA, Aglitti A, Zamor PJ, Xue Z, Schnell G, Jalundhwala YJ, Porcalla A, Mensa FJ, Persico M. Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection. Liver Int 2020;40:1032-41. [PMID: 31821716 DOI: 10.1111/liv.14320] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
36 Kileng H, Bernfort L, Gutteberg T, Moen OS, Kristiansen MG, Paulssen EJ, Berg LK, Florholmen J, Goll R. Future complications of chronic hepatitis C in a low-risk area: projections from the hepatitis c study in Northern Norway. BMC Infect Dis 2017;17:624. [PMID: 28915795 DOI: 10.1186/s12879-017-2722-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
37 Nakamura Y, Mizuguchi T, Kawamoto M, Meguro M, Harada K, Ota S, Hirata K. Cluster analysis of indicators of liver functional and preoperative low branched-chain amino acid tyrosine ration indicate a high risk of early recurrence in analysis of 165 hepatocellular carcinoma patients after initial hepatectomy. Surgery. 2011;150:250-262. [PMID: 21801962 DOI: 10.1016/j.surg.2011.06.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
38 Sakamoto N, Tanaka Y, Nakagawa M, Yatsuhashi H, Nishiguchi S, Enomoto N, Azuma S, Nishimura-sakurai Y, Kakinuma S, Nishida N, Tokunaga K, Honda M, Ito K, Mizokami M, Watanabe M. ITPA gene variant protects against anemia induced by pegylated interferon-α and ribavirin therapy for Japanese patients with chronic hepatitis C: ITPA gene variant against anemia. Hepatology Research 2010;40:1063-71. [DOI: 10.1111/j.1872-034x.2010.00741.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
39 Chen CL, Chang WC, Yi CH, Hung JS, Liu TT, Lei WY, Hsu CS. Association of coffee consumption and liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B: A 5-year population-based cohort study. J Formos Med Assoc 2019;118:628-35. [PMID: 30122312 DOI: 10.1016/j.jfma.2018.08.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
40 Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, Lok AS, Wright EC, Su GL; HALT-C Trial Group. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut 2010;59:1401-9. [PMID: 20675691 DOI: 10.1136/gut.2010.207423] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 6.4] [Reference Citation Analysis]
41 Maor Y, Malnick SD, Melzer E, Leshno M. Treatment of Chronic Hepatitis C in the Aged - Does It Impact Life Expectancy? A Decision Analysis. PLoS One 2016;11:e0157832. [PMID: 27410963 DOI: 10.1371/journal.pone.0157832] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
42 Lleo A, Aglitti A, Aghemo A, Maisonneuve P, Bruno S, Persico M;  collaborators. Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. Dig Liver Dis. 2019;51:310-317. [PMID: 30473220 DOI: 10.1016/j.dld.2018.10.014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
43 Hézode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, De Ledinghen V, Poynard T, Samuel D, Bourliere M. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology. 2014;147:132-142.e4. [PMID: 24704719 DOI: 10.1053/j.gastro.2014.03.051] [Cited by in Crossref: 198] [Cited by in F6Publishing: 175] [Article Influence: 28.3] [Reference Citation Analysis]
44 Anjo J, Café A, Carvalho A, Doroana M, Fraga J, Gíria J, Marinho R, Santos S, Velosa J. O impacto da hepatite C em Portugal. GE Jornal Português de Gastrenterologia 2014;21:44-54. [DOI: 10.1016/j.jpg.2014.03.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
45 Wen S, Cheng L, Hsu J, Lai H, Shih P, Tsai C, Kuo W. Assessment of baseline pretreatment factors and on-treatment virological response to predict sustained virological response in patients with chronic hepatitis C treated with pegylated interferon and ribavirin. Advances in Digestive Medicine 2017;4:4-11. [DOI: 10.1002/aid2.12004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Nagaoki Y, Aikata H, Kobayashi T, Fukuhara T, Masaki K, Tanaka M, Naeshiro N, Nakahara T, Honda Y, Miyaki D, Kawaoka T, Takaki S, Tsuge M, Hiramatsu A, Imamura M, Hyogo H, Kawakami Y, Takahashi S, Ochi H, Chayama K. Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosis. J Gastroenterol 2013;48:847-55. [PMID: 23053422 DOI: 10.1007/s00535-012-0679-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
47 Wisløff T, White R, Dalgard O, Amundsen EJ, Meijerink H, Kløvstad H. Feasibility of reaching world health organization targets for hepatitis C and the cost-effectiveness of alternative strategies. J Viral Hepat 2018;25:1066-77. [PMID: 29624813 DOI: 10.1111/jvh.12904] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
48 Dam Fialla A, Schaffalitzky de Muckadell OB, Touborg Lassen A. Incidence, etiology and mortality of cirrhosis: a population-based cohort study. Scand J Gastroenterol. 2012;47:702-709. [PMID: 22428859 DOI: 10.3109/00365521.2012.661759] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 4.8] [Reference Citation Analysis]
49 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol 2014;20:89-136. [PMID: 25032178 DOI: 10.3350/cmh.2014.20.2.89] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
50 Hsiang JC, Bai WW, Raos Z, Stableforth W, Upton A, Selvaratnam S, Gane EJ, Gerred SJ. Epidemiology, disease burden and outcomes of cirrhosis in a large secondary care hospital in South Auckland, New Zealand: Cirrhosis outcomes in New Zealand. Intern Med J 2015;45:160-9. [DOI: 10.1111/imj.12624] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
51 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1685] [Article Influence: 707.3] [Reference Citation Analysis]
52 Kim S, Kim S, Song I, Chun K. Comparison of survival outcomes after anatomical resection and non-anatomical resection in patients with hepatocellular carcinoma. Korean J Hepatobiliary Pancreat Surg 2015;19:161-6. [PMID: 26693235 DOI: 10.14701/kjhbps.2015.19.4.161] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
53 Trinchet J, Bourcier V, Chaffaut C, Ait Ahmed M, Allam S, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki J, Zarski J, Goria O, Calès P, Péron J, Alric L, Bourlière M, Mathurin P, Blanc J, Abergel A, Serfaty L, Mallat A, Grangé J, Buffet C, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Thiefin G, Hillaire S, Di Martino V, Nahon P, Chevret S; and the ANRS CO12 CirVir Group. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort): HEPATOLOGY, Vol. XX, No. X, 2015 TRINCHET ET AL. Hepatology 2015;62:737-50. [DOI: 10.1002/hep.27743] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 10.2] [Reference Citation Analysis]
54 Mahlich J, Kamae I, Rossi B. A NEW HEALTH TECHNOLOGY ASSESSMENT SYSTEM FOR JAPAN? SIMULATING THE POTENTIAL IMPACT ON THE PRICE OF SIMEPREVIR. Int J Technol Assess Health Care 2017;33:121-7. [DOI: 10.1017/s0266462317000174] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Yamamoto M, Sakamoto N, Nakamura T, Itsui Y, Nakagawa M, Nishimura-sakurai Y, Kakinuma S, Azuma S, Tsuchiya K, Kato T, Wakita T, Watanabe M. Studies on virus kinetics using infectious fluorescence-tagged hepatitis C virus cell culture: Fluorescence-tagged HCV kinetics. Hepatology Research 2011;41:258-69. [DOI: 10.1111/j.1872-034x.2010.00771.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
56 Vilana R, Forner A, García Á, Ayuso C, Bru C. Carcinoma hepatocelular: diagnóstico, estadificación y estrategia terapéutica. Radiología 2010;52:385-98. [DOI: 10.1016/j.rx.2010.05.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
57 Uto H, Stuver SO, Hayashi K, Kumagai K, Sasaki F, Kanmura S, Numata M, Moriuchi A, Hasegawa S, Oketani M, Ido A, Kusumoto K, Hasuike S, Nagata K, Kohara M, Tsubouchi H. Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study. Hepatology 2009;50:393-9. [PMID: 19585614 DOI: 10.1002/hep.23002] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 3.4] [Reference Citation Analysis]
58 D'Ambrosio R, Aghemo A, Rumi MG, Ronchi G, Donato MF, Paradis V, Colombo M, Bedossa P. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology. 2012;56:532-543. [PMID: 22271347 DOI: 10.1002/hep.25606] [Cited by in Crossref: 261] [Cited by in F6Publishing: 229] [Article Influence: 29.0] [Reference Citation Analysis]
59 European Association for Study of Liver. European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48:599-641. [PMID: 22424278 DOI: 10.1016/j.ejca.2011.12.021] [Cited by in Crossref: 273] [Cited by in F6Publishing: 253] [Article Influence: 30.3] [Reference Citation Analysis]
60 Calzadilla-Bertot L, Vilar-Gomez E, Wong VW, Romero-Gomez M, Aller-de la Fuente R, Wong GL, Castellanos M, Eslam M, Desai AP, Jeffrey GP, George J, Chalasani N, Adams LA. ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis. Hepatology 2021;73:2238-50. [PMID: 32978796 DOI: 10.1002/hep.31576] [Reference Citation Analysis]
61 Pompili M, Nicolardi E, Abbate V, Miele L, Riccardi L, Covino M, De Matthaeis N, Grieco A, Landolfi R, Rapaccini GL. Ethanol injection is highly effective for hepatocellular carcinoma smaller than 2 cm. World J Gastroenterol 2011;17:3126-32. [PMID: 21912455 DOI: 10.3748/wjg.v17.i26.3126] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
62 Giannini EG, Bodini G, Corbo M, Savarino V, Risso D, Di Nolfo MA, Del Poggio P, Benvegn㙠L, Farinati F, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; FOR THE ITALIAN LIVER CANCER (ITA.LI.CA.) GROUP. Impact of evidence-based medicine on the treatment of patients with unresectable hepatocellular carcinoma. Alimentary Pharmacology & Therapeutics 2010;31:493-501. [DOI: 10.1111/j.1365-2036.2009.04198.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
63 Nakamura J, Kobayashi K, Toyabe S, Aoyagi Y, Akazawa K. The cost-effectiveness of the new protocol reflecting rapid virologic response to peginterferon alpha-2b and ribavirin for chronic hepatitis C. Eur J Gastroenterol Hepatol 2007;19:733-9. [PMID: 17700257 DOI: 10.1097/MEG.0b013e3282748f1f] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
64 D’amico G, Morabito A, D’amico M, Pasta L, Malizia G, Rebora P, Valsecchi MG. New concepts on the clinical course and stratification of compensated and decompensated cirrhosis. Hepatol Int 2018;12:34-43. [DOI: 10.1007/s12072-017-9808-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 7.8] [Reference Citation Analysis]
65 Sharma SA, Kowgier M, Hansen BE, Brouwer WP, Maan R, Wong D, Shah H, Khalili K, Yim C, Heathcote EJ, Janssen HL, Sherman M, Hirschfield GM, Feld JJ. Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. Journal of Hepatology 2018;68:92-9. [DOI: 10.1016/j.jhep.2017.07.033] [Cited by in Crossref: 36] [Cited by in F6Publishing: 43] [Article Influence: 12.0] [Reference Citation Analysis]
66 Syed E, Rahbin N, Weiland O, Carlsson T, Oksanen A, Birk M, Davidsdottir L, Hagen K, Hultcrantz R, Aleman S. Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosis. Scand J Gastroenterol. 2008;43:1378-1386. [PMID: 18615358 DOI: 10.1080/00365520802245395] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
67 Giannini EG, Basso M, Bazzica M, Contini P, Marenco S, Savarino V, Picciotto A. Successful antiviral therapy determines a significant decrease in squamous cell carcinoma antigen-associated (SCCA) variants’ serum levels in anti-HCV positive cirrhotic patients. J Viral Hepat. 2010;17:563-568. [PMID: 19840364 DOI: 10.1111/j.1365-2893.2009.01217.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
68 . Guideline 3: Preventing HCV transmission in hemodialysis units. Kidney International 2008;73:S46-52. [DOI: 10.1038/ki.2008.86] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
69 Vera-llonch M, Martin M, Aggarwal J, Donepudi M, Bayliss M, Goss T, Younossi Z. Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. Aliment Pharmacol Ther 2013;38:124-33. [DOI: 10.1111/apt.12354] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
70 Sebhatu P, Martin MT. Genotype 1 hepatitis C virus and the pharmacist's role in treatment. Am J Health Syst Pharm 2016;73:764-74. [PMID: 27126832 DOI: 10.2146/ajhp150704] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
71 Liu T, Yao M, Liu S, Wang L, Wang L, Hou J, Ma X, Jia J, Zhao J, Zhuang H, Lu F. Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma. Oncotarget. 2017;8:16498-16506. [PMID: 28157705 DOI: 10.18632/oncotarget.14954] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
72 Noronha Ferreira C, Marinho RT, Cortez-Pinto H, Ferreira P, Dias MS, Vasconcelos M, Alexandrino P, Serejo F, Pedro AJ, Gonçalves A, Palma S, Leite I, Reis D, Damião F, Valente A, Xavier Brito L, Baldaia C, Fatela N, Ramalho F, Velosa J. Incidence, predictive factors and clinical significance of development of portal vein thrombosis in cirrhosis: A prospective study. Liver Int 2019;39:1459-67. [PMID: 31021512 DOI: 10.1111/liv.14121] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 9.5] [Reference Citation Analysis]
73 Athanasakis K, Ferrante SA, Kyriopoulos II, Petrakis I, Hill M, Retsa MP, Kyriopoulos J. Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis. Clin Ther 2015;37:1529-40. [PMID: 26031617 DOI: 10.1016/j.clinthera.2015.05.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
74 Tieu HV, Laeyendecker O, Nandi V, Rose R, Fernandez R, Lynch B, Hoover DR, Frye V, Koblin BA. Prevalence and mapping of hepatitis C infections among men who have sex with men in New York City. PLoS One 2018;13:e0200269. [PMID: 30020960 DOI: 10.1371/journal.pone.0200269] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
75 Hallager S, Ladelund S, Christensen PB, Kjær M, Thorup Roege B, Grønbæk KE, Belard E, Barfod TS, Madsen LG, Gerstoft J, Tarp B, Krarup HB, Weis N. Liver-related morbidity and mortality in patients with chronic hepatitis C and cirrhosis with and without sustained virologic response. Clin Epidemiol 2017;9:501-16. [PMID: 29123424 DOI: 10.2147/CLEP.S132072] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 3.8] [Reference Citation Analysis]
76 Braks RE, Ganne-Carrie N, Fontaine H, Paries J, Grando-Lemaire V, Beaugrand M, Pol S, Trinchet JC. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol 2007;13:5648-53. [PMID: 17948941 DOI: 10.3748/wjg.v13.i42.5648] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 51] [Article Influence: 4.4] [Reference Citation Analysis]
77 Kim DY, Kim HJ, Jeong SE, Kim SG, Kim HJ, Sinn DH, Lee YJ, Jeong WK, Choi KS, Heo N, Kim DJ, Kim YS, Kim YB, Kim YJ, Kim H, Park M, Lee CW, Tak WY, Chung JH, Kim SY, Kim Y, Lee W, Kim HS. The Korean guideline for hepatocellular carcinoma surveillance. J Korean Med Assoc 2015;58:385. [DOI: 10.5124/jkma.2015.58.5.385] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
78 Hézode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, Poynard T, Samuel D, Bourlière M. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol. 2013;59:434-441. [PMID: 23669289 DOI: 10.1016/j.jhep.2013.04.035] [Cited by in Crossref: 341] [Cited by in F6Publishing: 317] [Article Influence: 42.6] [Reference Citation Analysis]
79 Kristiansen MG, Gutteberg TJ, Mortensen L, Berg LK, Goll R, Florholmen J. Clinical outcomes in a prospective study of community-acquired hepatitis C virus infection in Northern Norway. Scand J Gastroenterol 2010;45:746-51. [PMID: 20205506 DOI: 10.3109/00365521003690699] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
80 Fernández-Rodríguez CM, Alonso S, Martinez SM, Forns X, Sanchez-Tapias JM, Rincón D, Rodriguez-Caravaca G, Bárcena R, Serra MA, Romero-Gómez M. Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. Am J Gastroenterol. 2010;105:2164-1272; quiz 2173. [PMID: 20700116 DOI: 10.1038/ajg.2010.294] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 4.4] [Reference Citation Analysis]
81 Schackman BR, Leff JA, Barter DM, DiLorenzo MA, Feaster DJ, Metsch LR, Freedberg KA, Linas BP. Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. Addiction 2015;110:129-43. [PMID: 25291977 DOI: 10.1111/add.12754] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
82 Brook G, Bhagani S, Kulasegaram R, Torkington A, Mutimer D, Hodges E, Hesketh L, Farnworth S, Sullivan V, Gore C, Devitt E, Sullivan AK; Clinical Effectiveness Group British Association for Sexual Health and HIV. United Kingdom National Guideline on the Management of the viral hepatitides A, B and C 2015. Int J STD AIDS 2016;27:501-25. [PMID: 26745988 DOI: 10.1177/0956462415624250] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
83 Mariano A, Scalia Tomba G, Tosti ME, Spada E, Mele A. Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy. Scand J Infect Dis. 2009;41:689-699. [PMID: 19579149 DOI: 10.1080/00365540903095358] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
84 Tapper EB, Parikh ND, Sengupta N, Mellinger J, Ratz D, Lok AS, Su GL. A risk score to predict the development of hepatic encephalopathy in a population‐based cohort of patients with cirrhosis. Hepatology 2018;68:1498-507. [DOI: 10.1002/hep.29628] [Cited by in Crossref: 34] [Cited by in F6Publishing: 20] [Article Influence: 11.3] [Reference Citation Analysis]
85 Peters L, Rockstroh JK. Biomarkers of fibrosis and impaired liver function in chronic hepatitis C: how well do they predict clinical outcomes?: . Current Opinion in HIV and AIDS 2010;5:517-23. [DOI: 10.1097/coh.0b013e32833e3ee6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
86 Louis C, Dewas S, Mirabel X, Lacornerie T, Adenis A, Bonodeau F, Lartigau E. Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results. Technol Cancer Res Treat. 2010;9:479-487. [PMID: 20815419 DOI: 10.1177/153303461000900506] [Cited by in Crossref: 86] [Cited by in F6Publishing: 74] [Article Influence: 7.8] [Reference Citation Analysis]
87 Giannini EG, Basso M, Savarino V, Picciotto A. Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension. J Intern Med. 2009;266:537-546. [PMID: 19849774 DOI: 10.1111/j.1365-2796.2009.02130.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
88 Nishida T. Diagnosis and Clinical Implications of Diabetes in Liver Cirrhosis: A Focus on the Oral Glucose Tolerance Test. J Endocr Soc 2017;1:886-96. [PMID: 29264539 DOI: 10.1210/js.2017-00183] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
89 Polo ML, Laufer N. Extrahepatic manifestations of HCV: the role of direct acting antivirals. Expert Rev Anti Infect Ther. 2017;15:737-746. [PMID: 28696154 DOI: 10.1080/14787210.2017.1354697] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
90 Fründt T, Krause L, Hussey E, Steinbach B, Köhler D, von Felden J, Schulze K, Lohse AW, Wege H, Schwarzenbach H. Diagnostic and Prognostic Value of miR-16, miR-146a, miR-192 and miR-221 in Exosomes of Hepatocellular Carcinoma and Liver Cirrhosis Patients. Cancers (Basel) 2021;13:2484. [PMID: 34069692 DOI: 10.3390/cancers13102484] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Cheng PN, Chiu HC, Chiu YC, Chen SC, Chen Y. Comparison of FIB-4 and transient elastography in evaluating liver fibrosis of chronic hepatitis C subjects in community. PLoS One 2018;13:e0206947. [PMID: 30403744 DOI: 10.1371/journal.pone.0206947] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
92 Hedenstierna M, Nangarhari A, Weiland O, Aleman S. Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C. Clin Infect Dis 2016;63:723-9. [DOI: 10.1093/cid/ciw362] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
93 Jackson WE, Everson GT. Sofosbuvir and velpatasvir for the treatment of hepatitis C. Expert Review of Gastroenterology & Hepatology 2017;11:501-5. [DOI: 10.1080/17474124.2017.1326817] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
94 Page CM, Hughes BL, Rhee EHJ, Kuller JA. Hepatitis C in Pregnancy: Review of Current Knowledge and Updated Recommendations for Management. Obstet Gynecol Surv 2017;72:347-55. [PMID: 28661549 DOI: 10.1097/OGX.0000000000000442] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
95 Calvaruso V, Petta S, Cacciola I, Cabibbo G, Cartabellotta F, Distefano M, Scifo G, Di Rosolini MA, Russello M, Prestileo T, Madonia S, Malizia G, Montineri A, Digiacomo A, Licata A, Benanti F, Bertino G, Enea M, Battaglia S, Squadrito G, Raimondo G, Cammà C, Craxì A, Di Marco V; Rete Sicilia Selezione Terapia - HCV (RESIST-HCV). Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort. J Viral Hepat 2021;28:1190-9. [PMID: 33896097 DOI: 10.1111/jvh.13523] [Reference Citation Analysis]
96 Díaz-González Á, Forner A. Surveillance for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2016;30:1001-10. [PMID: 27938779 DOI: 10.1016/j.bpg.2016.10.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
97 . Introduction. Kidney International 2008;73:S6-9. [DOI: 10.1038/ki.2008.83] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
98 Russo MW. Antiviral therapy for hepatitis C is associated with improved clinical outcomes in patients with advanced fibrosis. Expert Rev Gastroenterol Hepatol. 2010;4:535-539. [PMID: 20932138 DOI: 10.1586/egh.10.60] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
99 Calzadilla-Bertot L, Vilar-Gomez E, Torres-Gonzalez A, Socias-Lopez M, Diago M, Adams LA, Romero-Gomez M. Impaired glucose metabolism increases risk of hepatic decompensation and death in patients with compensated hepatitis C virus-related cirrhosis. Dig Liver Dis 2016;48:283-90. [PMID: 26797261 DOI: 10.1016/j.dld.2015.12.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
100 Odhiambo R, Chhatwal J, Ferrante SA, El Khoury A, Elbasha E. Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary. JHEOR 2013;1:62-82. [DOI: 10.36469/9854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
101 Smith A, Varney E, Zand K, Lewis T, Sirous R, York J, Florez E, Abou Elkassem A, Howard-claudio CM, Roda M, Parker E, Scortegagna E, Joyner D, Sandlin D, Newsome A, Brewster P, Lirette ST, Griswold M. Precision analysis of a quantitative CT liver surface nodularity score. Abdom Radiol 2018;43:3307-16. [DOI: 10.1007/s00261-018-1617-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
102 Hemming AW, Berumen J, Mekeel K. Hepatitis B and Hepatocellular Carcinoma. Clin Liver Dis. 2016;20:703-720. [PMID: 27742009 DOI: 10.1016/j.cld.2016.06.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
103 Dongiovanni P, Romeo S, Valenti L. Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. World J Gastroenterol 2014;20:12945-55. [PMID: 25278690 DOI: 10.3748/wjg.v20.i36.12945] [Cited by in CrossRef: 82] [Cited by in F6Publishing: 65] [Article Influence: 13.7] [Reference Citation Analysis]
104 Wirth TC, Manns MP. The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma. Ann Oncol 2016;27:1467-74. [PMID: 27226385 DOI: 10.1093/annonc/mdw219] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
105 Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, Escorsell A, Garcia-Pagan JC, Makuch R, Patch D, Matloff DS, Bosch J; Portal Hypertension Collaborative Group. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133:481-488. [PMID: 17681169 DOI: 10.1053/j.gastro.2007.05.024] [Cited by in Crossref: 643] [Cited by in F6Publishing: 495] [Article Influence: 45.9] [Reference Citation Analysis]
106 Stroffolini T, Almasio PL, Persico M, Bollani S, Benvegnù L, Di Costanzo G, Pastore G, Aghemo A, Stornaiuolo G, Mangia A. Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis. Am J Gastroenterol. 2008;103:1966-1972. [PMID: 18637087 DOI: 10.1111/j.1572-0241.2008.01912.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
107 Demirtas CO, Brunetto MR. Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it? WJG 2021;27:5536-54. [DOI: 10.3748/wjg.v27.i33.5536] [Reference Citation Analysis]
108 Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, Marrero JA. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37-47. [PMID: 19392863 DOI: 10.1111/j.1365-2036.2009.04014.x] [Cited by in Crossref: 454] [Cited by in F6Publishing: 365] [Article Influence: 37.8] [Reference Citation Analysis]
109 Senecal DL, Morelli J. Hepatitis C virus infection: A current review: . Journal of the American Academy of Physician Assistants 2007;20:21-5. [DOI: 10.1097/01720610-200710000-00017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
110 Davis GL, Alter MJ, El–serag H, Poynard T, Jennings LW. Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression. Gastroenterology 2010;138:513-521.e6. [DOI: 10.1053/j.gastro.2009.09.067] [Cited by in Crossref: 649] [Cited by in F6Publishing: 598] [Article Influence: 59.0] [Reference Citation Analysis]
111 Velosa J, Macedo G. Elimination of Hepatitis C in Portugal: An Urban Legend? GE Port J Gastroenterol 2020;27:166-71. [PMID: 32509922 DOI: 10.1159/000505582] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 Armandi A, Rosso C, Caviglia GP, Bugianesi E. Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease. Metabolites 2021;11:155. [PMID: 33800465 DOI: 10.3390/metabo11030155] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
113 Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM, Wright EC, Stoddard AM, Sterling RK, Di Bisceglie AM, Bonkovsky HL, Morishima C, Morgan TR, Dienstag JL; HALT-C Trial Group. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology 2010;138:136-46. [PMID: 19766643 DOI: 10.1053/j.gastro.2009.09.007] [Cited by in Crossref: 70] [Cited by in F6Publishing: 64] [Article Influence: 5.8] [Reference Citation Analysis]
114 Ott P. What is the Value of Country-Based Surveillance Programmes? In: Williams R, Taylor-robinson SD, editors. Clinical Dilemmas in Primary Liver Cancer. Oxford: Wiley-Blackwell; 2011. pp. 97-104. [DOI: 10.1002/9781119962205.ch14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
115 Mancuso A, Perricone G. Hepatocellular Carcinoma and Liver Transplantation: State of the Art. J Clin Transl Hepatol 2014;2:176-81. [PMID: 26357625 DOI: 10.14218/JCTH.2014.00013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
116 Cacoub P, Nahon P, Layese R, Blaise L, Desbois AC, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S. Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients. Am Heart J. 2018;198:4-17. [PMID: 29653647 DOI: 10.1016/j.ahj.2017.10.024] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
117 Gomez EV, Gonzalez AT, Bertot LC, Yasells Garcia A, Rodriguez YS, Perez YM. Arterial blood pressure is closely related to ascites development in compensated HCV-related cirrhosis. PLoS One 2014;9:e95736. [PMID: 24755710 DOI: 10.1371/journal.pone.0095736] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
118 Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, Guyader D, Fontaine H, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki J, Zarski J, Leroy V, Riachi G, Calès P, Péron J, Alric L, Bourlière M, Mathurin P, Dharancy S, Blanc J, Abergel A, Serfaty L, Mallat A, Grangé J, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Bernard-chabert B, Zucman D, Di Martino V, Thibaut V, Salmon D, Ziol M, Sutton A, Pol S, Roudot-thoraval F, Nahon P, Marcellin P, Guyader D, Pol S, Fontaine H, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki J, Zarski J, Leroy V, Riachi G, Calès P, Péron J, Alric L, Bourlière M, Mathurin P, Blanc J, Abergel A, Serfaty L, Mallat A, Grangé J, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Thiefin G, Hillaire S, Di Martino V. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. Gastroenterology 2017;152:142-156.e2. [DOI: 10.1053/j.gastro.2016.09.009] [Cited by in Crossref: 275] [Cited by in F6Publishing: 235] [Article Influence: 68.8] [Reference Citation Analysis]
119 Di Costanzo GG, Tortora R, Iodice L, Lanza AG, Lampasi F, Tartaglione MT, Picciotto FP, Mattera S, De Luca M. Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice. Dig Liver Dis. 2012;44:788-792. [PMID: 22579445 DOI: 10.1016/j.dld.2012.04.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
120 Méndez-Sánchez N, Ridruejo E, Alves de Mattos A, Chávez-Tapia NC, Zapata R, Paraná R, Mastai R, Strauss E, Guevara-Casallas LG, Daruich J, Gadano A, Parise ER, Uribe M, Aguilar-Olivos NE, Dagher L, Ferraz-Neto BH, Valdés-Sánchez M, Sánchez-Avila JF. Latin American Association for the Study of the Liver (LAASL) clinical practice guidelines: management of hepatocellular carcinoma. Ann Hepatol 2014;13 Suppl 1:S4-40. [PMID: 24998696 [PMID: 24998696 DOI: 10.1016/s1665-2681(19)30919-6] [Cited by in Crossref: 17] [Article Influence: 2.8] [Reference Citation Analysis]
121 Aspinall EJ, Hutchinson SJ, Janjua NZ, Grebely J, Yu A, Alavi M, Amin J, Goldberg DJ, Innes H, Law M, Walter SR, Krajden M, Dore GJ. Trends in mortality after diagnosis of hepatitis C virus infection: An international comparison and implications for monitoring the population impact of treatment. Journal of Hepatology 2015;62:269-77. [DOI: 10.1016/j.jhep.2014.09.001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
122 Fukuda H, Moriwaki K. Cost-Effectiveness Analysis of Safety-Engineered Devices. Infect Control Hosp Epidemiol 2016;37:1012-21. [PMID: 27226284 DOI: 10.1017/ice.2016.110] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
123 Hassan A, Tsuda Y, Asai A, Yokohama K, Nakamura K, Sujishi T, Ohama H, Tsuchimoto Y, Fukunishi S, Abdelaal UM, Arafa UA, Hassan AT, Kassem AM, Higuchi K. Effects of Oral L-Carnitine on Liver Functions after Transarterial Chemoembolization in Intermediate-Stage HCC Patients. Mediators Inflamm 2015;2015:608216. [PMID: 26664151 DOI: 10.1155/2015/608216] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
124 Di Costanzo GG, Tortora R, Morisco F, Addario L, Guarino M, Cordone G, Falco L, Caporaso N. Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma. Target Oncol. 2017;12:61-67. [PMID: 27503006 DOI: 10.1007/s11523-016-0454-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
125 Liu C, Duan LG, Lu WS, Yan LN, Xiao GQ, Jiang L, Yang J, Yang JY. Prognosis evaluation in patients with hepatocellular carcinoma after hepatectomy: comparison of BCLC, TNM and Hangzhou criteria staging systems. PLoS One 2014;9:e103228. [PMID: 25133493 DOI: 10.1371/journal.pone.0103228] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
126 Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C, Stoddard AM, Everhart JE; HALT-C Trial Group. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 2011;54:396-405. [PMID: 21520194 DOI: 10.1002/hep.24370] [Cited by in Crossref: 111] [Cited by in F6Publishing: 106] [Article Influence: 11.1] [Reference Citation Analysis]
127 Hsu CS, Lang HC, Huang KY, Chao YC, Chen CL. Risks of hepatocellular carcinoma and cirrhosis-associated complications in patients with rheumatoid arthritis: a 10-year population-based cohort study in Taiwan. Hepatol Int 2018;12:531-43. [PMID: 30426396 DOI: 10.1007/s12072-018-9905-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
128 Elbasha EH, Chhatwal J, Ferrante SA, El Khoury AC, Laires PA. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal. Appl Health Econ Health Policy 2013;11:65-78. [PMID: 23355388 DOI: 10.1007/s40258-012-0007-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
129 Tampaki M, Savvanis S, Koskinas J. Impact of direct-acting antiviral agents on the development of hepatocellular carcinoma: evidence and pathophysiological issues. Ann Gastroenterol 2018;31:670-9. [PMID: 30386116 DOI: 10.20524/aog.2018.0306] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
130 Imperiale TF, Klein RW, Chalasani N. Cost-effectiveness analysis of variceal ligation vs. beta-blockers for primary prevention of variceal bleeding. Hepatology. 2007;45:870-878. [PMID: 17393528 DOI: 10.1002/hep.21605] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
131 Di Costanzo GG, de Stefano G, Tortora R, Farella N, Addario L, Lampasi F, Lanza AG, Cordone G, Imparato M, Caporaso N. Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma. Future Oncology 2015;11:943-51. [DOI: 10.2217/fon.14.291] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
132 Patil M, Sheth KA, Adarsh CK. Elevated alpha fetoprotein, no hepatocellular carcinoma. J Clin Exp Hepatol 2013;3:162-4. [PMID: 25755491 DOI: 10.1016/j.jceh.2013.02.246] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
133 Manesis EK, Papatheodoridis GV, Touloumi G, Karafoulidou A, Ketikoglou J, Kitis GE, Antoniou A, Kanatakis S, Koutsounas SJ, Vafiadis I. Natural course of treated and untreated chronic HCV infection: results of the nationwide Hepnet.Greece cohort study. Aliment Pharmacol Ther. 2009;29:1121-1130. [PMID: 19222410 DOI: 10.1111/j.1365-2036.2009.03974.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
134 Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, Boyer N, Asselah T, Martinot-Peignoux M, Maylin S. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol. 2010;52:652-657. [PMID: 20346533 DOI: 10.1016/j.jhep.2009.12.028] [Cited by in Crossref: 231] [Cited by in F6Publishing: 218] [Article Influence: 21.0] [Reference Citation Analysis]
135 Ponziani FR, Annicchiarico EB, Siciliano M, D'Aversa F, Pompili M, Gasbarrini A. Treatment of hepatitis C in compensated cirrhotic patients is equally effective before and after liver transplantation. World J Gastroenterol 2013;19:3255-62. [PMID: 23745027 DOI: 10.3748/wjg.v19.i21.3255] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
136 Mcconachie SM, Wilhelm SM, Kale-pradhan PB. New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir. Expert Review of Clinical Pharmacology 2015;9:287-302. [DOI: 10.1586/17512433.2016.1129272] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
137 Bonacini M, Kim Y, Pitney C, McKoin L, Tran M, Landis C. Wirelessly Observed Therapy to Optimize Adherence and Target Interventions for Oral Hepatitis C Treatment: Observational Pilot Study. J Med Internet Res 2020;22:e15532. [PMID: 32352385 DOI: 10.2196/15532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
138 Hanafy AS, Seleem WM, Basha MAA, Marei AM. Residual hepatitis C virus in peripheral blood mononuclear cell as a risk factor for hepatocellular carcinoma after achieving a sustained virological response: a dogma or fiction. Eur J Gastroenterol Hepatol 2019;31:1275-82. [PMID: 31149912 DOI: 10.1097/MEG.0000000000001459] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Giallongo S, Lo Re O, Vinciguerra M. Macro Histone Variants: Emerging Rheostats of Gastrointestinal Cancers. Cancers (Basel) 2019;11:E676. [PMID: 31096699 DOI: 10.3390/cancers11050676] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
140 Ferenci P, Ferenci S, Datz C, Rezman I, Oberaigner W, Strauss R. Morbidity and mortality in paid Austrian plasma donors infected with hepatitis C at plasma donation in the 1970s. Journal of Hepatology 2007;47:31-6. [DOI: 10.1016/j.jhep.2007.01.023] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
141 Shiffman ML, Benhamou Y. Cure of HCV related liver disease. Liver Int 2015;35 Suppl 1:71-7. [PMID: 25529090 DOI: 10.1111/liv.12734] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
142 Vandenbulcke H, Moreno C, Colle I, Knebel JF, Francque S, Sersté T, George C, de Galocsy C, Laleman W, Delwaide J, Orlent H, Lasser L, Trépo E, Van Vlierberghe H, Michielsen P, van Gossum M, de Vos M, Marot A, Doerig C, Henrion J, Deltenre P. Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study. J Hepatol 2016;65:543-51. [PMID: 27180899 DOI: 10.1016/j.jhep.2016.04.031] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
143 Alberti A, Piovesan S. Increased incidence of liver cancer after successful DAA treatment of chronic hepatitis C: Fact or fiction? Liver Int 2017;37:802-8. [DOI: 10.1111/liv.13390] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
144 Zakaria S, El-Sisi A. Rebamipide retards CCl4-induced hepatic fibrosis in rats: Possible role for PGE2. J Immunotoxicol. 2016;13:453-462. [PMID: 26849241 DOI: 10.3109/1547691x.2015.1128022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
145 Pal S, Ramachandran J, Kurien RT, Eapen A, Ramakrishna B, Keshava SN, Goel A, Sajith KG, Eapen CE. Hepatocellular carcinoma continues to be diagnosed in the advanced stage: profile of hepatocellular carcinoma in a tertiary care hospital in South India. Trop Doct 2013;43:25-6. [PMID: 23443626 DOI: 10.1177/0049475512473600] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
146 Shiffman ML. The next wave of hepatitis C virus: The epidemic of intravenous drug use. Liver Int 2018;38:34-9. [DOI: 10.1111/liv.13647] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 5.7] [Reference Citation Analysis]
147 Lampertico P, Aghemo A, Viganò M, Colombo M. HBV and HCV therapy. Viruses 2009;1:484-509. [PMID: 21994557 DOI: 10.3390/v1030484] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
148 Assoumou SA, Tasillo A, Leff JA, Schackman BR, Drainoni ML, Horsburgh CR, Barry MA, Regis C, Kim AY, Marshall A, Saxena S, Smith PC, Linas BP. Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings. Clin Infect Dis. 2018;66:376-384. [PMID: 29020317 DOI: 10.1093/cid/cix798] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 22.0] [Reference Citation Analysis]
149 Kutala BK, Guedj J, Asselah T, Boyer N, Mouri F, Martinot-Peignoux M, Valla D, Marcellin P, Duval X. Impact of treatment against hepatitis C virus on overall survival of naive patients with advanced liver disease. Antimicrob Agents Chemother 2015;59:803-10. [PMID: 25403673 DOI: 10.1128/AAC.04027-14] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
150 Tandon P, Doucette K, Fassbender K, Vandermeer B, Durec T, Dryden DM. Granulocyte colony‐stimulating factor for hepatitis C therapy‐associated neutropenia: systematic review and economic evaluation. Journal of Viral Hepatitis 2011;18. [DOI: 10.1111/j.1365-2893.2011.01445.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
151 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol. 2016;22:76-139. [PMID: 27044763 DOI: 10.3350/cmh.2016.22.1.76] [Cited by in Crossref: 42] [Cited by in F6Publishing: 51] [Article Influence: 8.4] [Reference Citation Analysis]
152 Kato H, Yoshida H, Taniguch H, Nomura R, Sato K, Suzuki I, Nakata R. Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma. World J Gastroenterol 2015;21:13101-12. [PMID: 26673627 DOI: 10.3748/wjg.v21.i46.13101] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
153 Yao M, Wang L, Leung PSC, Li Y, Liu S, Wang L, Guo X, Zhou G, Yan Y, Guan G, Chen X, Bowlus CL, Liu T, Jia J, Gershwin ME, Ma X, Zhao J, Lu F. The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review. Clin Rev Allergy Immunol. 2018;54:282-294. [PMID: 29256057 DOI: 10.1007/s12016-017-8655-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
154 Zarski J, David-tchouda S, Trocme C, Margier J, Vilotitch A, Hilleret M, Cagnot C, Boursier V, Ziol M, Sutton A, Layese R, Audureau E, Roudot-thoraval F, Nahon P. Non-invasive fibrosis tests to predict complications in compensated post-hepatitis C cirrhosis. Clinics and Research in Hepatology and Gastroenterology 2020;44:524-31. [DOI: 10.1016/j.clinre.2019.11.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
155 Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol. 2020;72:250-261. [PMID: 31954490 DOI: 10.1016/j.jhep.2019.08.025] [Cited by in Crossref: 131] [Cited by in F6Publishing: 118] [Article Influence: 131.0] [Reference Citation Analysis]
156 Ronot M, Pommier R, Dioguardi Burgio M, Purcell Y, Nahon P, Vilgrain V. Hepatocellular carcinoma surveillance with ultrasound-cost-effectiveness, high-risk populations, uptake. Br J Radiol 2018;91:20170436. [PMID: 29446324 DOI: 10.1259/bjr.20170436] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
157 Carrillo FJ, Mattos AA, Vianey AF, Vezozzo DC, Marinho F, Souto FJ, Cotrim HP, Coelho HS, Silva I, Garcia JH. Brazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinoma. Arq Gastroenterol. 2015;52 Suppl 1:2-14. [PMID: 26959803 DOI: 10.1590/s0004-28032015000500001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
158 Wisløff T, White R, Dalgard O, Amundsen EJ, Meijerink H, Løvlie AL, Kløvstad H. Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway. Pharmacoeconomics 2018;36:591-601. [PMID: 29396744 DOI: 10.1007/s40273-017-0604-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
159 Prenner SB, Kulik L. Hepatocellular carcinoma in the wait-listed patient with hepatitis C virus. Curr Opin Organ Transplant 2018;23:237-43. [PMID: 29406448 DOI: 10.1097/MOT.0000000000000505] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
160 Di Costanzo GG, Tortora R, D’Adamo G, De Luca M, Lampasi F, Addario L, Galeota Lanza A, Picciotto FP, Tartaglione MT, Cordone G. Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: a randomized trial. J Gastroenterol Hepatol. 2015;30:559-565. [PMID: 25251043 DOI: 10.1111/jgh.12791] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 6.7] [Reference Citation Analysis]
161 Toshikuni N, Arisawa T, Tsutsumi M. Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality. World J Gastroenterol. 2014;20:2876-2887. [PMID: 24659879 DOI: 10.3748/wjg.v20.i11.2876] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
162 Aghemo A, Lampertico P, Colombo M. Assessing long-term treatment efficacy in chronic hepatitis B and C: Between evidence and common sense. Journal of Hepatology 2012;57:1326-35. [DOI: 10.1016/j.jhep.2012.06.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
163 Samonakis DN, Koulentaki M, Coucoutsi C, Augoustaki A, Baritaki C, Digenakis E, Papiamonis N, Fragaki M, Matrella E, Tzardi M. Clinical outcomes of compensated and decompensated cirrhosis: A long term study. World J Hepatol. 2014;6:504-512. [PMID: 25068002 DOI: 10.4254/wjh.v6.i7.504] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
164 Linas BP, Barter DM, Morgan JR, Pho MT, Leff JA, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Freedberg KA, Kim AY. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med 2015;162:619-29. [PMID: 25820703 DOI: 10.7326/M14-1313] [Cited by in Crossref: 76] [Cited by in F6Publishing: 40] [Article Influence: 12.7] [Reference Citation Analysis]
165 Seto WK, Lai CL, Fung J, Hung I, Yuen J, Young J, Wong DK, Yuen MF. Natural history of chronic hepatitis C: genotype 1 versus genotype 6. J Hepatol. 2010;53:444-448. [PMID: 20554340 DOI: 10.1016/j.jhep.2010.04.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
166 Vilar Gomez E, Sanchez Rodriguez Y, Torres Gonzalez A, Calzadilla Bertot L, Arus Soler E, Martinez Perez Y, Yasells Garcia A, Abreu Vazquez Mdel R. Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: a randomised and controlled trial. BMJ Open. 2011;1:e000140. [PMID: 22021873 DOI: 10.1136/bmjopen-2011-000140] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
167 Orsi E, Grancini V, Menini S, Aghemo A, Pugliese G. Hepatogenous diabetes: Is it time to separate it from type 2 diabetes? Liver Int. 2017;37:950-962. [PMID: 27943508 DOI: 10.1111/liv.13337] [Cited by in Crossref: 36] [Cited by in F6Publishing: 23] [Article Influence: 7.2] [Reference Citation Analysis]
168 Hedenstierna M, Nangarhari A, El-Sabini A, Weiland O, Aleman S. Cirrhosis, high age and high body mass index are risk factors for persisting advanced fibrosis after sustained virological response in chronic hepatitis C. J Viral Hepat 2018;25:802-10. [PMID: 29406590 DOI: 10.1111/jvh.12879] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
169 Giannitrapani L, Soresi M, La Spada E, Tripodo C, Montalto G. Progressive visceral leishmaniasis misdiagnosed as cirrhosis of the liver: a case report. J Med Case Rep 2009;3:7265. [PMID: 19830157 DOI: 10.4076/1752-1947-3-7265] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
170 Koo JK, Kim JH, Choi YJ, Lee CI, Yang JH, Yoon HY, Choi HJ, Ko SY, Choe WH, Kwon SY, Lee CH. Predictive value of Refit Model for End-Stage Liver Disease, Refit Model for End-Stage Liver Disease-Na, and pre-existing scoring system for 3-month mortality in Korean patients with cirrhosis: Value of Refit Model for End-stage Liver Disease. J Gastroenterol Hepatol 2013;28:1209-16. [DOI: 10.1111/jgh.12156] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
171 Firpi RJ, Nelson DR. Current and Future Hepatitis C Therapies. Archives of Medical Research 2007;38:678-90. [DOI: 10.1016/j.arcmed.2006.09.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
172 Nowicki TK, Markiet K, Szurowska E. Diagnostic Imaging of Hepatocellular Carcinoma - A Pictorial Essay. Curr Med Imaging Rev 2017;13:140-53. [PMID: 28553196 DOI: 10.2174/1573405612666160720123748] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
173 Rimola J, Forner A, Tremosini S, Reig M, Vilana R, Bianchi L, Rodríguez-lope C, Solé M, Ayuso C, Bruix J. Non-invasive diagnosis of hepatocellular carcinoma ⩽2cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. Journal of Hepatology 2012;56:1317-23. [DOI: 10.1016/j.jhep.2012.01.004] [Cited by in Crossref: 118] [Cited by in F6Publishing: 105] [Article Influence: 13.1] [Reference Citation Analysis]
174 Mourad A, Deuffic-Burban S, Ganne-Carrié N, Renaut-Vantroys T, Rosa I, Bouvier AM, Launoy G, Cattan S, Louvet A, Dharancy S, Trinchet JC, Yazdanpanah Y, Mathurin P. Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: a modeling approach. Hepatology 2014;59:1471-81. [PMID: 24677195 DOI: 10.1002/hep.26944] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
175 Terrault NA, Hassanein TI. Management of the patient with SVR. Journal of Hepatology 2016;65:S120-9. [DOI: 10.1016/j.jhep.2016.08.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 6.6] [Reference Citation Analysis]
176 Tomaszewski KJ, Deniz B, Tomanovich P, Graham CS. Comparison of current US risk strategy to screen for hepatitis C virus with a hypothetical targeted birth cohort strategy. Am J Public Health 2012;102:e101-6. [PMID: 22813094 DOI: 10.2105/AJPH.2011.300488] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
177 Meijerink H, White RA, Løvlie A, de Blasio BF, Dalgard O, Amundsen EJ, Melum E, Kløvstad H. Modelling the burden of hepatitis C infection among people who inject drugs in Norway, 1973-2030. BMC Infect Dis 2017;17:541. [PMID: 28774261 DOI: 10.1186/s12879-017-2631-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
178 Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, de Franchis R, Ronchi G, Colombo M. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009;136:1629-1638. [PMID: 19208358 DOI: 10.1053/j.gastro.2009.01.052] [Cited by in Crossref: 184] [Cited by in F6Publishing: 151] [Article Influence: 15.3] [Reference Citation Analysis]
179 Seo YS, Kim MS, Yoo HJ, Jang WI, Paik EK, Han CJ, Lee BH. Radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma: a Markov model-based analysis. Cancer Med 2016;5:3094-101. [PMID: 27709795 DOI: 10.1002/cam4.893] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
180 Rimola J, Forner A, Reig M, Vilana R, de Lope CR, Ayuso C, Bruix J. Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology. 2009;50:791-798. [PMID: 19610049 DOI: 10.1002/hep.23071] [Cited by in Crossref: 201] [Cited by in F6Publishing: 160] [Article Influence: 16.8] [Reference Citation Analysis]
181 Ray SC, Thomas DL. Hepatitis C. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier; 2010. pp. 2157-85. [DOI: 10.1016/b978-0-443-06839-3.00154-5] [Cited by in Crossref: 5] [Article Influence: 0.5] [Reference Citation Analysis]
182 Finkelmeier F, Dultz G, Peiffer KH, Kronenberger B, Krauss F, Zeuzem S, Sarrazin C, Vermehren J, Waidmann O. Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals. Liver Cancer 2018;7:190-204. [PMID: 29888208 DOI: 10.1159/000486812] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
183 Yuen MF, Liu SH, Seto WK, Mak LY, Corman SL, Hsu DC, Lee MYK, Khan TK, Puenpatom A. Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong. Dig Dis Sci 2021;66:1315-26. [PMID: 32385703 DOI: 10.1007/s10620-020-06281-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
184 Toshikuni N, Izumi A, Nishino K, Inada N, Sakanoue R, Yamato R, Suehiro M, Kawanaka M, Yamada G. Comparison of outcomes between patients with alcoholic cirrhosis and those with hepatitis C virus-related cirrhosis. J Gastroenterol Hepatol. 2009;24:1276-1283. [PMID: 19486451 DOI: 10.1111/j.1440-1746.2009.05851.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 3.8] [Reference Citation Analysis]
185 Jacenik D, Fichna J. Chemerin in immune response and gastrointestinal pathophysiology. Clin Chim Acta 2020;504:146-53. [PMID: 32070869 DOI: 10.1016/j.cca.2020.02.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
186 Li J, Wu DD, Zhang JX, Wang J, Ma JJ, Hu X, Dong WG. Mitochondrial pathway mediated by reactive oxygen species involvement in α-hederin-induced apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 2018;24:1901-10. [PMID: 29740205 DOI: 10.3748/wjg.v24.i17.1901] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
187 Malik SM, Gupte PA, de Vera ME, Ahmad J. Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2009;7:800-806. [PMID: 19281869 DOI: 10.1016/j.cgh.2009.02.025] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
188 Laursen TL, Siggaard CB, Kazankov K, Sandahl TD, Møller HJ, Tarp B, Kristensen LH, Laursen AL, Leutscher P, Grønbæk H. Time‐dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct‐acting antiviral therapy of chronic hepatitis C. J Viral Hepat 2019;27:28-35. [DOI: 10.1111/jvh.13204] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
189 Chhatwal J, Ferrante SA, Brass C, El Khoury AC, Burroughs M, Bacon B, Esteban-Mur R, Elbasha EH. Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value Health 2013;16:973-86. [PMID: 24041347 DOI: 10.1016/j.jval.2013.07.006] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 6.4] [Reference Citation Analysis]
190 Kalafateli M, Buzzetti E, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis. Cochrane Database Syst Rev 2017;3:CD011644. [PMID: 28285495 DOI: 10.1002/14651858.CD011644.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
191 Marinho RT, Barreira DP. Hepatitis C, stigma and cure. World J Gastroenterol. 2013;19:6703-6709. [PMID: 24187444 DOI: 10.3748/wjg.v19.i40.6703] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 47] [Article Influence: 7.7] [Reference Citation Analysis]
192 Elkrief L, Chouinard P, Bendersky N, Hajage D, Larroque B, Babany G, Kutala B, Francoz C, Boyer N, Moreau R, Durand F, Marcellin P, Rautou PE, Valla D. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology. 2014;60:823-831. [PMID: 24841704 DOI: 10.1002/hep.27228] [Cited by in Crossref: 85] [Cited by in F6Publishing: 80] [Article Influence: 12.1] [Reference Citation Analysis]
193 Gurusamy KS, Wilson E, Koretz RL, Allen VB, Davidson BR, Burroughs AK, Gluud C. Is sustained virological response a marker of treatment efficacy in patients with chronic hepatitis C viral infection with no response or relapse to previous antiviral intervention? PLoS One. 2013;8:e83313. [PMID: 24349487 DOI: 10.1371/journal.pone.0083313] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
194 García-samaniego J, Forns X. Hepatitis C virus and human immunodeficiency virus: The Un-Won Battle. Hepatology 2007;46:611-4. [DOI: 10.1002/hep.21818] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
195 Ferre-aracil C, Lledó J, Aguilera L, Garcia-paredes A, Rodríguez-santiago E, Graus J, García-gonzález M, Nuño J, López-buenadicha A, López-hervás P, Rodríguez-gandía M, Gea F, Albillos A. Current allocation policy is favorable for patients with hepatocellular carcinoma waiting for liver transplantation. Digestive and Liver Disease 2018;50:1345-50. [DOI: 10.1016/j.dld.2018.04.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
196 Elzouki AN, Elgamay SM, Zorgani A, Elahmer O. Hepatitis B and C status among health care workers in the five main hospitals in eastern Libya. J Infect Public Health. 2014;7:534-541. [PMID: 25151657 DOI: 10.1016/j.jiph.2014.07.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
197 Lee SS, Jeong S, Jang ES, Kim YS, Lee YJ, Jung EU, Kim IH, Bae SH, Lee HC, Kee M, Kang C. Prospective cohort study on the outcomes of hepatitis C virus-related cirrhosis in South Korea: Outcomes of HCV-related cirrhosis. J Gastroenterol Hepatol 2015;30:1281-7. [DOI: 10.1111/jgh.12950] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
198 Mücke MM, Mücke VT, Lange CM, Zeuzem S. Managing hepatitis C in patients with the complications of cirrhosis. Liver Int 2018;38 Suppl 1:14-20. [PMID: 29427491 DOI: 10.1111/liv.13636] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
199 Ayuso C, Rimola J, García-Criado A. Imaging of HCC. Abdom Imaging. 2012;37:215-230. [PMID: 21909721 DOI: 10.1007/s00261-011-9794-x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
200 Holvoet T, Raevens S, Vandewynckel YP, Van Biesen W, Geboes K, Van Vlierberghe H. Systematic review of guidelines for management of intermediate hepatocellular carcinoma using the Appraisal of Guidelines Research and Evaluation II instrument. Dig Liver Dis. 2015;47:877-883. [PMID: 26250948 DOI: 10.1016/j.dld.2015.07.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
201 Younossi ZM, Stepanova M, Marcellin P, Afdhal N, Kowdley KV, Zeuzem S, Hunt SL. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials. Hepatology. 2015;61:1798-1808. [PMID: 25627448 DOI: 10.1002/hep.27724] [Cited by in Crossref: 101] [Cited by in F6Publishing: 96] [Article Influence: 16.8] [Reference Citation Analysis]
202 Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, Lok AS, Wright EC, Su GL. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut. 2010;59:1401-1409. [PMID: 20675691 DOI: 10.1136/gut.2010.207423.] [Reference Citation Analysis]
203 Nakamura J, Toyabe S, Aoyagi Y, Akazawa K. Economic impact of extended treatment with peginterferon α-2a and ribavirin for slow hepatitis C virologic responders. J Viral Hepat 2008;15:293-9. [DOI: 10.1111/j.1365-2893.2007.00943.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
204 Maimaiti R, Zhang Y, Pan K, Wubuli M, Andersson R. Frequent coinfection with hepatitis among HIV-positive patients in Urumqi, China. J Int Assoc Provid AIDS Care. 2015;12:58-61. [PMID: 23087203 DOI: 10.1177/1545109712446176] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
205 Hernández-gea V, Aracil C, Colomo A, Garupera I, Poca M, Torras X, Miñana J, Guarner C, Villanueva C. Development of Ascites in Compensated Cirrhosis With Severe Portal Hypertension Treated With β-Blockers. American Journal of Gastroenterology 2012;107:418-27. [DOI: 10.1038/ajg.2011.456] [Cited by in Crossref: 87] [Cited by in F6Publishing: 62] [Article Influence: 9.7] [Reference Citation Analysis]
206 D'Ambrosio R, Aghemo A. Treatment of patients with HCV related cirrhosis: many rewards with very few risks. Hepat Mon 2012;12:361-8. [PMID: 22879824 DOI: 10.5812/hepatmon.6095] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
207 Kim KA. [Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Indications for Treatment]. Korean J Gastroenterol 2016;67:123-6. [PMID: 26996180 DOI: 10.4166/kjg.2016.67.3.123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
208 Hanje AJ, Yao FY. Current approach to down-staging of hepatocellular carcinoma prior to liver transplantation. Curr Opin Organ Transplant 2008;13:234-40. [PMID: 18685309 DOI: 10.1097/MOT.0b013e3282fc2633] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
209 Caviglia GP, Olivero A, Rosso C, Bosco C, Ribaldone DG, Fagoonee S. Laboratory evidence of Helicobacter species infection in hepatocellular carcinoma. Minerva Biotecnol 2018;30. [DOI: 10.23736/s1120-4826.18.02428-x] [Cited by in Crossref: 12] [Article Influence: 4.0] [Reference Citation Analysis]
210 Piffer S, Mazza A, Dell'Anna L. Serological screening for hepatitis C during pregnancy: Seroprevalence and maternal and neonatal outcomes in 45,000 pregnant women. Eur J Obstet Gynecol Reprod Biol 2020;254:195-9. [PMID: 33017709 DOI: 10.1016/j.ejogrb.2020.09.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
211 Syed TA, Bashir MH, Farooqui SM, Chen A, Chen S, Nusrat S, Fazili J. Treatment Outcomes of Hepatitis C-Infected Patients in Specialty Clinic vs. Primary Care Physician Clinic: A Comparative Analysis. Gastroenterol Res Pract 2019;2019:8434602. [PMID: 31281352 DOI: 10.1155/2019/8434602] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
212 François C, Descamps V, Brochot E, Bernard I, Canva V, Mathurin P, Castelain S, Duverlie G. Relationship between the hepatitis C viral load and the serum interferon concentration during the first week of peginterferon-alpha-2b-ribavirin combination therapy. J Med Virol 2010;82:1640-6. [PMID: 20827759 DOI: 10.1002/jmv.21837] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
213 Fassio E. Hepatitis C and hepatocellular carcinoma. Annals of Hepatology 2010;9:S119-22. [DOI: 10.1016/s1665-2681(19)31736-3] [Cited by in Crossref: 26] [Article Influence: 2.4] [Reference Citation Analysis]
214 Nilsson E, Anderson H, Sargenti K, Lindgren S, Prytz H. Clinical course and mortality by etiology of liver cirrhosis in Sweden: a population based, long-term follow-up study of 1317 patients. Aliment Pharmacol Ther 2019;49:1421-30. [DOI: 10.1111/apt.15255] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
215 Aghemo A, Colombo M. Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. Semin Immunopathol 2013;35:111-20. [DOI: 10.1007/s00281-012-0330-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
216 Sukowati CHC, El-Khobar KE, Tiribelli C. Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells. World J Stem Cells 2021;13:795-824. [PMID: 34367478 DOI: 10.4252/wjsc.v13.i7.795] [Reference Citation Analysis]
217 Ippolito D, Inchingolo R, Grazioli L, Drago SG, Nardella M, Gatti M, Faletti R. Recent advances in non-invasive magnetic resonance imaging assessment of hepatocellular carcinoma. World J Gastroenterol. 2018;24:2413-2426. [PMID: 29930464 DOI: 10.3748/wjg.v24.i23.2413] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
218 Persico M, Bruno S, Costantino A, Mazza M, Almasio PL. The impact of antiviral therapy and the influence of metabolic cofactors on the outcome of chronic HCV infection. Int J Hepatol 2011;2011:314301. [PMID: 22164334 DOI: 10.4061/2011/314301] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
219 Peired AJ, Lazzeri E, Guzzi F, Anders HJ, Romagnani P. From kidney injury to kidney cancer. Kidney Int 2021;100:55-66. [PMID: 33794229 DOI: 10.1016/j.kint.2021.03.011] [Reference Citation Analysis]
220 Di Costanzo GG, Tortora R. Intermediate hepatocellular carcinoma: How to choose the best treatment modality? World J Hepatol. 2015;7:1184-1191. [PMID: 26019734 DOI: 10.4254/wjh.v7.i9.1184] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
221 Di Marco V, Calvaruso V, Ferraro D, Bavetta MG, Cabibbo G, Conte E, Cammà C, Grimaudo S, Pipitone RM, Simone F, Peralta S, Arini A, Craxì A. Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension. Gastroenterology 2016;151:130-139.e2. [PMID: 27039970 DOI: 10.1053/j.gastro.2016.03.036] [Cited by in Crossref: 94] [Cited by in F6Publishing: 89] [Article Influence: 18.8] [Reference Citation Analysis]
222 Martin DJ, Weideman R, Crook T, Brown G. Relationship of hepatic fibrosis, cirrhosis, and mortality with cholecystectomy in patients with hepatitis C virus infection. Eur J Gastroenterol Hepatol 2016;28:181-6. [PMID: 26566061 DOI: 10.1097/MEG.0000000000000512] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
223 Wong VW, Chan WK, Chitturi S, Chawla Y, Dan YY, Duseja A, Fan J, Goh KL, Hamaguchi M, Hashimoto E, Kim SU, Lesmana LA, Lin YC, Liu CJ, Ni YH, Sollano J, Wong SK, Wong GL, Chan HL, Farrell G. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33:70-85. [PMID: 28670712 DOI: 10.1111/jgh.13857] [Cited by in Crossref: 165] [Cited by in F6Publishing: 137] [Article Influence: 82.5] [Reference Citation Analysis]
224 Ziol M, Nault J, Aout M, Barget N, Tepper M, Martin A, Trinchet J, Ganne–carrié N, Vicaut E, Beaugrand M, N'kontchou G. Intermediate Hepatobiliary Cells Predict an Increased Risk of Hepatocarcinogenesis in Patients With Hepatitis C Virus-Related Cirrhosis. Gastroenterology 2010;139:335-343.e2. [DOI: 10.1053/j.gastro.2010.04.012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
225 Lange N, Dufour JF. Changing Epidemiology of HCC: How to Screen and Identify Patients at Risk? Dig Dis Sci 2019;64:903-9. [PMID: 30863952 DOI: 10.1007/s10620-019-05515-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
226 Boucher E, Forner A, Reig M, Bruix J. New drugs for the treatment of hepatocellular carcinoma. Liver Int 2009;29 Suppl 1:148-58. [PMID: 19207980 DOI: 10.1111/j.1478-3231.2008.01929.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
227 Elbahrawy A, Ibrahim MK, Eliwa A, Alboraie M, Madian A, Aly HH. Current situation of viral hepatitis in Egypt. Microbiol Immunol 2021;65:352-72. [PMID: 33990999 DOI: 10.1111/1348-0421.12916] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
228 Gatta LA, Hughes BL. Premature Rupture of Membranes with Concurrent Viral Infection. Obstet Gynecol Clin North Am 2020;47:605-23. [PMID: 33121648 DOI: 10.1016/j.ogc.2020.08.006] [Reference Citation Analysis]
229 Motoyama H, Tamori A, Kubo S, Uchida-Kobayashi S, Takemura S, Tanaka S, Ohfuji S, Teranishi Y, Kozuka R, Kawamura E, Hagihara A, Morikawa H, Enomoto M, Murakami Y, Kawada N. Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication. PLoS One 2018;13:e0194163. [PMID: 29534101 DOI: 10.1371/journal.pone.0194163] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
230 Park JH, Park MS, Lee SJ, Jeong WK, Lee JY, Park MJ, Han K, Nam CM, Park SH, Lee KH. Contrast-enhanced US with Perfluorobutane(Sonazoid) used as a surveillance test for Hepatocellular Carcinoma (HCC) in Cirrhosis (SCAN): an exploratory cross-sectional study for a diagnostic trial. BMC Cancer 2017;17:279. [PMID: 28420329 DOI: 10.1186/s12885-017-3267-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
231 Society for Maternal-Fetal Medicine (SMFM), Hughes BL, Page CM, Kuller JA. Hepatitis C in pregnancy: screening, treatment, and management. Am J Obstet Gynecol. 2017;217:B2-B12. [PMID: 28782502 DOI: 10.1016/j.ajog.2017.07.039] [Cited by in Crossref: 88] [Cited by in F6Publishing: 76] [Article Influence: 22.0] [Reference Citation Analysis]
232 Bruno S, Zuin M, Crosignani A, Rossi S, Zadra F, Roffi L, Borzio M, Redaelli A, Chiesa A, Silini EM, Almasio PL, Maisonneuve P. Predicting Mortality Risk in Patients With Compensated HCV-Induced Cirrhosis: A Long-Term Prospective Study. Am J Gastroenterol 2009;104:1147-58. [DOI: 10.1038/ajg.2009.31] [Cited by in Crossref: 115] [Cited by in F6Publishing: 100] [Article Influence: 9.6] [Reference Citation Analysis]
233 Pfeiffenberger J, Mogler C, Gotthardt DN, Schulze-Bergkamen H, Litwin T, Reuner U, Hefter H, Huster D, Schemmer P, Członkowska A, Schirmacher P, Stremmel W, Cassiman D, Weiss KH. Hepatobiliary malignancies in Wilson disease. Liver Int 2015;35:1615-22. [PMID: 25369181 DOI: 10.1111/liv.12727] [Cited by in Crossref: 49] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
234 Lazarus JV, Picchio C, Dillon JF, Rockstroh JK, Weis N, Buti M. Too many people with viral hepatitis are diagnosed late — with dire consequences. Nat Rev Gastroenterol Hepatol 2019;16:451-2. [DOI: 10.1038/s41575-019-0177-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
235 Burza MA, Motta BM, Mancina RM, Pingitore P, Pirazzi C, Lepore SM, Spagnuolo R, Doldo P, Russo C, Lazzaro V. DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection. Hepatology. 2016;63:418-427. [PMID: 26517016 DOI: 10.1002/hep.28322] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
236 Rodríguez-Tajes S, Pocurull A, Castillo J, Casanova G, Vega L, Lens S, Mariño Z, Londoño MC, Forner A, Torres F, Forns X. Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions by 2025. J Hepatol 2020;73:1360-7. [PMID: 32697948 DOI: 10.1016/j.jhep.2020.07.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
237 Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017;14:122-132. [PMID: 27924080 DOI: 10.1038/nrgastro.2016.176] [Cited by in Crossref: 196] [Cited by in F6Publishing: 185] [Article Influence: 39.2] [Reference Citation Analysis]
238 Linas BP, Barter DM, Leff JA, Assoumou SA, Salomon JA, Weinstein MC, Kim AY, Schackman BR. The hepatitis C cascade of care: identifying priorities to improve clinical outcomes. PLoS One 2014;9:e97317. [PMID: 24842841 DOI: 10.1371/journal.pone.0097317] [Cited by in Crossref: 77] [Cited by in F6Publishing: 77] [Article Influence: 11.0] [Reference Citation Analysis]
239 Gómez Rodríguez R, Romero Gutiérrez M, González de Frutos C, de Artaza Varasa T, de la Cruz Perez G, Ciampi Dopazo JJ, Lanciego Pérez C, Gómez Moreno AZ. [Clinical characteristics, staging and treatment of patients with hepatocellular carcinoma in clinical practice. Prospective study of 136 patients]. Gastroenterol Hepatol. 2011;34:524-531. [PMID: 21940068 DOI: 10.1016/j.gastrohep.2011.06.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
240 Forner A, Díaz-gonzález Á, Liccioni A, Vilana R. Prognosis prediction and staging. Best Practice & Research Clinical Gastroenterology 2014;28:855-65. [DOI: 10.1016/j.bpg.2014.08.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
241 Gellad ZF, Muir AJ, McHutchison JG, Sievert W, Sharara AI, Brown KA, Flisiak R, Jacobson IM, Kershenobich D, Manns MP, Schulman KA, Reed SD. Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response. Value Health 2012;15:876-86. [PMID: 22999138 DOI: 10.1016/j.jval.2012.06.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
242 Montasser IF, Ibrahim AA, Farid HM, Al Balakosy AM. De novo hepatocellular carcinoma in cirrhotic hepatitis C virus: Are directly acting antivirals beneficial? Clin Res Hepatol Gastroenterol 2021;45:101517. [PMID: 32900667 DOI: 10.1016/j.clinre.2020.07.022] [Reference Citation Analysis]
243 Sangiovanni A, Iavarone M. Hepatitis C virus genotype 1b, cirrhosis, and risk of hepatocellular carcinoma. Hepatology 2008;47:357; author reply 357-8. [PMID: 18161732 DOI: 10.1002/hep.22060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
244 Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther. 2010;32:344-355. [PMID: 20497143 DOI: 10.1111/j.1365-2036.2010.04370.x] [Cited by in Crossref: 122] [Cited by in F6Publishing: 123] [Article Influence: 11.1] [Reference Citation Analysis]
245 Hassanin HAM, Koko M, Abdalla M, Mu W, Jiang B. Detarium microcarpum: A novel source of nutrition and medicine: A review. Food Chem 2019;274:900-6. [PMID: 30373026 DOI: 10.1016/j.foodchem.2018.09.070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
246 Runge M, Krensel M, Westermann C, Bindl D, Nagels K, Augustin M, Nienhaus A. Cost-Effectiveness Analysis of Direct-Acting Antiviral Agents for Occupational Hepatitis C Infections in Germany. Int J Environ Res Public Health 2020;17:E440. [PMID: 31936470 DOI: 10.3390/ijerph17020440] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
247 Costentin CE, Sogni P, Falissard B, Barbare JC, Bendersky N, Farges O, Goutte N. Geographical Disparities of Outcomes of Hepatocellular Carcinoma in France: The Heavier Burden of Alcohol Compared to Hepatitis C. Dig Dis Sci 2020;65:301-11. [PMID: 31346950 DOI: 10.1007/s10620-019-05724-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
248 Finotti M, Vitale A, Volk M, Cillo U. A 2020 update on liver transplant for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2020;14:885-900. [PMID: 32662680 DOI: 10.1080/17474124.2020.1791704] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
249 Cho YK, Kim JK, Kim WT, Chung JW. Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology. 2010;51:1284-1290. [PMID: 20099299 DOI: 10.1002/hep.23466] [Cited by in Crossref: 171] [Cited by in F6Publishing: 134] [Article Influence: 15.5] [Reference Citation Analysis]
250 Bruno S, Facciotto C. The natural course of HCV infection and the need for treatment. Annals of Hepatology 2008;7:114-9. [DOI: 10.1016/s1665-2681(19)31865-4] [Cited by in Crossref: 17] [Article Influence: 1.3] [Reference Citation Analysis]
251 Xu R, Zhang Z, Wang FS. Liver fibrosis: mechanisms of immune-mediated liver injury. Cell Mol Immunol 2012;9:296-301. [PMID: 22157623 DOI: 10.1038/cmi.2011.53] [Cited by in Crossref: 84] [Cited by in F6Publishing: 76] [Article Influence: 8.4] [Reference Citation Analysis]
252 Villani R, Cavallone F, Sangineto M, Fioravanti G, Romano AD, Serviddio G. Management of intermediate-stage hepatocellular carcinoma in the elderly with transcatheter arterial chemoembolization failure: Retreatment or switching to systemic therapy? Int J Clin Pract 2021;75:e13733. [PMID: 32981175 DOI: 10.1111/ijcp.13733] [Reference Citation Analysis]
253 Iavarone M, Viganò M, Piazza N, Occhipinti V, Sangiovanni A, Maggioni M, D'Ambrosio G, Forzenigo LV, Motta F, Lampertico P, Rumi MG, Colombo M. Contrast imaging techniques to diagnose hepatocellular carcinoma in cirrhotics outside regular surveillance. Ann Hepatol 2019;18:318-24. [PMID: 31036496 DOI: 10.1016/j.aohep.2018.09.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
254 Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011;54:396-405. [PMID: 21520194 DOI: 10.1002/hep.24370.24370] [Reference Citation Analysis]
255 White CM, Kilgore ML. PillCam ESO versus esophagogastro duodenoscopy in esophageal variceal screening: A decision analysis.J Clin Gastroenterol. 2009;43:975-981. [PMID: 19661814 DOI: 10.1097/MCG.0b013e3181a7ed09] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
256 Kim DY, Han KH. Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer 2012;1:2-14. [PMID: 24159567 DOI: 10.1159/000339016] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 10.4] [Reference Citation Analysis]
257 Tarantino G, Gentile A, Capone D, Basile V, Tarantino M, Di Minno MN, Cuocolo A, Conca P. Does protracted antiviral therapy impact on HCV-related liver cirrhosis progression? World J Gastroenterol 2007;13:4903-8. [PMID: 17828823 DOI: 10.3748/wjg.v13.i36.4903] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
258 . Guideline 4: Management of HCV-infected patients before and after kidney transplantation. Kidney International 2008;73:S53-68. [DOI: 10.1038/ki.2008.87] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
259 Davis GL, Roberts WL. The Healthcare Burden Imposed by Liver Disease in Aging Baby Boomers. Curr Gastroenterol Rep 2010;12:1-6. [DOI: 10.1007/s11894-009-0087-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
260 Srivastava S, Thakkar B, Yeoh KG, Ho KY, Teh M, Soong R, Salto-tellez M. Expression of proteins associated with hypoxia and Wnt pathway activation is of prognostic significance in hepatocellular carcinoma. Virchows Arch 2015;466:541-8. [DOI: 10.1007/s00428-015-1745-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
261 Cabrera R, Nelson DR. Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2010;31:461-76. [PMID: 19925500 DOI: 10.1111/j.1365-2036.2009.04200.x] [Cited by in Crossref: 129] [Cited by in F6Publishing: 120] [Article Influence: 10.8] [Reference Citation Analysis]
262 Lens S, Berbel C, Forns X, García-pagán JC. Portal Hypertension Reverses Following Successful Antiviral Treatment for HCV: Fact or Fiction? Curr Hepatology Rep 2018;17:209-17. [DOI: 10.1007/s11901-018-0405-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
263 Mariano A, Caserta C, Pendino G, Vacalebre C, Surace P, Fiorillo M, Polito I, Surace M, Alicante S, Amante A, Foti G, Marra M, Gutamo G, Amato F, Messineo A, Mele A. Antiviral treatment for hepatitis C virus infection: Effectiveness at general population level in a highly endemic area. Digestive and Liver Disease 2009;41:509-15. [DOI: 10.1016/j.dld.2008.11.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
264 Merchante N, Rivero-Juárez A, Téllez F, Merino D, Ríos-Villegas MJ, Villalobos M, Omar M, Rincón P, Rivero A, Pérez-Pérez M, Raffo M, López-Montesinos I, Palacios R, Gómez-Vidal MA, Macías J, Pineda JA; Members of the HEPAVIR-Cirrhosis Study Group. Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis. J Antimicrob Chemother 2018;73:2435-43. [PMID: 29982683 DOI: 10.1093/jac/dky234] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
265 Takagi H, Kaji K, Nishimura N, Ishida K, Ogawa H, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H. The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects. Cells 2021;10:575. [PMID: 33807929 DOI: 10.3390/cells10030575] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
266 Kwon JH, Kim GM, Han K, Won JY, Kim MD, Lee DY, Lee J, Choi W, Kim YS, Kim DY, Han KH. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study. Cardiovasc Intervent Radiol. 2018;41:459-465. [PMID: 29067511 DOI: 10.1007/s00270-017-1826-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
267 Hallager S, Ladelund S, Kjaer M, Madsen LG, Belard E, Laursen AL, Gerstoft J, Røge BT, Grønbaek KE, Krarup HB, Christensen PB, Weis N. Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark: A nationwide cohort study. J Viral Hepat 2018;25:47-55. [PMID: 28750141 DOI: 10.1111/jvh.12764] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
268 Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, Ascione A, Santantonio T, Piccinino F, Andreone P, Mangia A, Gaeta GB, Persico M, Fagiuoli S, Almasio PL; on behalf of the Italian Association of the Study of the Liver Disease (AISF). Sustained virological response to interferon-α is associated with improved outcome in HCV-related cirrhosis: A retrospective study. Hepatology 2007;45:579-87. [DOI: 10.1002/hep.21492] [Cited by in Crossref: 473] [Cited by in F6Publishing: 419] [Article Influence: 33.8] [Reference Citation Analysis]
269 Cheek MA, Sharaf ML, Dobrikov MI, Shaw BR. Inhibition of hepatitis C viral RNA-dependent RNA polymerase by α-P-boranophosphate nucleotides: exploring a potential strategy for mechanism-based HCV drug design. Antiviral Res 2013;98:144-52. [PMID: 23466667 DOI: 10.1016/j.antiviral.2013.02.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
270 Wang R, Zang W, Hu B, Deng D, Ling X, Zhou H, Su M, Jiang J. Serum ESPL1 Can Be Used as a Biomarker for Patients With Hepatitis B Virus-Related Liver Cancer: A Chinese Case-Control Study. Technol Cancer Res Treat 2020;19:1533033820980785. [PMID: 33308056 DOI: 10.1177/1533033820980785] [Reference Citation Analysis]
271 Kalafateli M, Buzzetti E, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Pharmacological interventions for acute hepatitis C infection. Cochrane Database Syst Rev 2018;12:CD011644. [PMID: 30521693 DOI: 10.1002/14651858.CD011644.pub3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
272 Rennert J, Wiesinger I, Schicho A, Beyer LP, Wiggermann P, Stroszczynski C, Jung EM. Color coded perfusion imaging with contrast enhanced ultrasound (CEUS) for post-interventional success control following trans-arterial chemoembolization (TACE) of hepatocellular carcinoma. PLoS One 2019;14:e0217599. [PMID: 31181127 DOI: 10.1371/journal.pone.0217599] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
273 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
274 Welker MW, Luhne S, Lange CM, Vermehren J, Farnik H, Herrmann E, Welzel T, Zeuzem S, Sarrazin C. Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment. J Hepatol. 2016;64:790-799. [PMID: 26658684 DOI: 10.1016/j.jhep.2015.11.034] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 8.2] [Reference Citation Analysis]
275 Pineda JA, García-garcía JA, Aguilar-guisado M, Ríos-villegas MJ, Ruiz-morales J, Rivero A, del Valle J, Luque R, Rodríguez-baño J, González-serrano M, Camacho A, Macías J, Grilo I, Gómez-mateos JM; Grupo para el Estudio de las Hepatitis Víricas de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007;46:622-30. [DOI: 10.1002/hep.21757] [Cited by in Crossref: 143] [Cited by in F6Publishing: 130] [Article Influence: 10.2] [Reference Citation Analysis]
276 Elbasha E, Greaves W, Roth D, Nwankwo C. Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States. J Viral Hepat 2017;24:268-79. [PMID: 27966249 DOI: 10.1111/jvh.12639] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
277 Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol. 2012;26:401-412. [PMID: 23199500 DOI: 10.1016/j.bpg.2012.09.009] [Cited by in Crossref: 148] [Cited by in F6Publishing: 139] [Article Influence: 18.5] [Reference Citation Analysis]
278 Tabrizian P, Roayaie S, Schwartz ME. Current management of hepatocellular carcinoma. World J Gastroenterol. 2014;20:10223-10237. [PMID: 25132740 DOI: 10.3748/wjg.v20.i30.10223] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 39] [Article Influence: 7.2] [Reference Citation Analysis]
279 Bodzin AS, Busuttil RW. Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome. World J Hepatol. 2015;7:1157-1167. [PMID: 26019732 DOI: 10.4254/wjh.v7.i9.1157] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 8.2] [Reference Citation Analysis]
280 Vezali E, Aghemo A, Lampertico P, Colombo M. Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis? Clin Res Hepatol Gastroenterol 2011;35:455-64. [PMID: 21435968 DOI: 10.1016/j.clinre.2011.02.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
281 Piccinino F, Coppola N. Antiviral treatment of HCV-related cirrhosis. Digestive and Liver Disease 2007;39:S96-S101. [DOI: 10.1016/s1590-8658(07)80019-3] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
282 Deng LX, Mehta N. Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers. Dig Dis Sci 2020;65:3456-62. [PMID: 32860090 DOI: 10.1007/s10620-020-06550-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
283 Lleo A, de Boer YS, Liberal R, Colombo M. The risk of liver cancer in autoimmune liver diseases. Ther Adv Med Oncol 2019;11:1758835919861914. [PMID: 31320937 DOI: 10.1177/1758835919861914] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
284 Lim S, Kim SH, Kim Y, Cho YS, Kim TY, Jeong WK, Sohn JH. Coefficient of Variance as Quality Criterion for Evaluation of Advanced Hepatic Fibrosis Using 2D Shear-Wave Elastography: Coefficient of Variance as Quality Criterion for Liver Fibrosis. J Ultrasound Med 2018;37:355-62. [DOI: 10.1002/jum.14341] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
285 Zavaglia C, Silini E, Mangia A, Airoldi A, Piazzolla V, Vangeli M, Stigliano R, Foschi A, Mazzarelli C, Tinelli C. Prognostic factors of hepatic decompensation and hepatocellular carcinoma in patients with transfusion-acquired HCV infection. Liver Int 2014;34:e308-16. [PMID: 24529078 DOI: 10.1111/liv.12502] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
286 Chuang KT, Wang SN, Hsu SH, Wang LT. Impact of bromodomain-containing protein 4 (BRD4) and intestine-specific homeobox (ISX) expression on the prognosis of patients with hepatocellular carcinoma' for better clarity. Cancer Med 2021;10:5545-56. [PMID: 34173348 DOI: 10.1002/cam4.4094] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
287 Hatzakis A, Wait S, Bruix J, Buti M, Carballo M, Cavaleri M, Colombo M, Delarocque-Astagneau E, Dusheiko G, Esmat G, Esteban R, Goldberg D, Gore C, Lok AS, Manns M, Marcellin P, Papatheodoridis G, Peterle A, Prati D, Piorkowsky N, Rizzetto M, Roudot-Thoraval F, Soriano V, Thomas HC, Thursz M, Valla D, van Damme P, Veldhuijzen IK, Wedemeyer H, Wiessing L, Zanetti AR, Janssen HL. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat. 2011;18 Suppl 1:1-16. [PMID: 21824223 DOI: 10.1111/j.1365-2893.2011.01499.x] [Cited by in Crossref: 159] [Cited by in F6Publishing: 151] [Article Influence: 15.9] [Reference Citation Analysis]
288 Riaz M, Idrees M, Kanwal H, Kabir F. An overview of triple infection with hepatitis B, C and D viruses. Virol J. 2011;8:368. [PMID: 21791115 DOI: 10.1186/1743-422x-8-368] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
289 D'Amico G, Morabito A, D'Amico M, Pasta L, Malizia G, Rebora P, Valsecchi MG. Clinical states of cirrhosis and competing risks. J Hepatol. 2018;68:563-576. [PMID: 29111320 DOI: 10.1016/j.jhep.2017.10.020] [Cited by in Crossref: 116] [Cited by in F6Publishing: 88] [Article Influence: 29.0] [Reference Citation Analysis]
290 Gomez EV, Rodriguez YS, Bertot LC, Gonzalez AT, Perez YM, Soler EA, Garcia AY, Blanco LP. The natural history of compensated HCV-related cirrhosis: a prospective long-term study. J Hepatol. 2013;58:434-444. [PMID: 23111008 DOI: 10.1016/j.jhep.2012.10.023] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 5.9] [Reference Citation Analysis]
291 European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943. [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001] [Cited by in Crossref: 3642] [Cited by in F6Publishing: 3309] [Article Influence: 404.7] [Reference Citation Analysis]
292 Zhang S, Bastian ND, Griffin PM. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US. BMC Gastroenterol 2015;15:98. [PMID: 26239358 DOI: 10.1186/s12876-015-0320-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
293 Kulik LM, Mulcahy MF, Omary RA, Salem R. Emerging Approaches in Hepatocellular Carcinoma. Journal of Clinical Gastroenterology 2007;41:839-54. [DOI: 10.1097/mcg.0b013e318060ac52] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
294 Kaplan DE, Ikeda F, Li Y, Nakamoto N, Ganesan S, Valiga ME, Nunes FA, Rajender Reddy K, Chang KM. Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitis. J Hepatol. 2008;48:903-913. [PMID: 18384906 DOI: 10.1016/j.jhep.2008.01.030] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 4.5] [Reference Citation Analysis]
295 Marcellin P, Pequignot F, Delarocque-Astagneau E, Zarski JP, Ganne N, Hillon P, Antona D, Bovet M, Mechain M, Asselah T, Desenclos JC, Jougla E. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol. 2008;48:200-207. [PMID: 18086507 DOI: 10.1016/j.jhep.2007.09.010] [Cited by in Crossref: 113] [Cited by in F6Publishing: 99] [Article Influence: 8.1] [Reference Citation Analysis]
296 Kawaguchi I, Chayama K, Gonzalez YS, Virabhak S, Mitchell D, Yuen C, Kumada H. A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan. Adv Ther 2020;37:457-76. [PMID: 31808054 DOI: 10.1007/s12325-019-01166-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
297 D'ambrosio R, Colombo M. Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression? Liver Int 2016;36:783-90. [DOI: 10.1111/liv.13106] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
298 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014] [Reference Citation Analysis]
299 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014.122] [Cited by in Crossref: 247] [Cited by in F6Publishing: 235] [Article Influence: 35.3] [Reference Citation Analysis]
300 Trinchet JC, Ganne-Carrié N, Nahon P, N'kontchou G, Beaugrand M. Hepatocellular carcinoma in patients with hepatitis C virus-related chronic liver disease. World J Gastroenterol 2007;13:2455-60. [PMID: 17552029 DOI: 10.3748/wjg.v13.i17.2455] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
301 Pascual S, Herrera I, Irurzun J. New advances in hepatocellular carcinoma. World J Hepatol. 2016;8:421-438. [PMID: 27028578 DOI: 10.4254/wjh.v8.i9.421] [Cited by in Crossref: 81] [Cited by in F6Publishing: 66] [Article Influence: 16.2] [Reference Citation Analysis]
302 Zhang C, Wu J, Xu J, Xu J, Xian J, Xue S, Ye J. Association between Aspartate Aminotransferase-to-Platelet Ratio Index and Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis: A Meta-Analysis of Cohort Study. Dis Markers 2019;2019:2046825. [PMID: 31814857 DOI: 10.1155/2019/2046825] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
303 Tuma P, Jarrin I, Del Amo J, Vispo E, Medrano J, Martin-Carbonero L, Labarga P, Barreiro P, Soriano V. Survival of HIV-infected patients with compensated liver cirrhosis. AIDS. 2010;24:745-753. [PMID: 20154579 DOI: 10.1097/qad.0b013e3283366602] [Cited by in Crossref: 26] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
304 Gilabert M, Raoul JL. Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein. J Hepatocell Carcinoma 2018;5:91-8. [PMID: 30464931 DOI: 10.2147/JHC.S157413] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
305 Nudo CG, Cortes RA, Weppler D, Schiff ER, Tzakis AG, Regev A. Effect of pretransplant hepatitis C virus RNA status on posttransplant outcome. Transplant Proc 2008;40:1449-55. [PMID: 18589127 DOI: 10.1016/j.transproceed.2008.03.158] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
306 Sukowati CHC, Cabral LKD, Tiribelli C, Pascut D. Circulating Long and Circular Noncoding RNA as Non-Invasive Diagnostic Tools of Hepatocellular Carcinoma. Biomedicines 2021;9:90. [PMID: 33477833 DOI: 10.3390/biomedicines9010090] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
307 Bibault JE, Dewas S, Vautravers-Dewas C, Hollebecque A, Jarraya H, Lacornerie T, Lartigau E, Mirabel X. Stereotactic body radiation therapy for hepatocellular carcinoma: prognostic factors of local control, overall survival, and toxicity. PLoS One. 2013;8:e77472. [PMID: 24147002 DOI: 10.1371/journal.pone.0077472] [Cited by in Crossref: 76] [Cited by in F6Publishing: 62] [Article Influence: 9.5] [Reference Citation Analysis]
308 Cheung KF, Ye DW, Yang ZF, Lu L, Liu CH, Wang XL, Poon RT, Tong Y, Liu P, Chen YC. Therapeutic efficacy of Traditional Chinese Medicine 319 recipe on hepatic fibrosis induced by carbon tetrachloride in rats. J Ethnopharmacol. 2009;124:142-150. [PMID: 19501992 DOI: 10.1016/j.jep.2009.03.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
309 Pol S, Corouge M. Treatment of hepatitis C: perspectives. Med Mal Infect. 2014;44:449-454. [PMID: 25174659 DOI: 10.1016/j.medmal.2014.07.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
310 Zhou H, Jiang T, Li Q, Zhang C, Zhang C, Liu Y, Cao J, Sun Y, Jin P, Luo J, Pan M, Huang P. US-Based Deep Learning Model for Differentiating Hepatocellular Carcinoma (HCC) From Other Malignancy in Cirrhotic Patients. Front Oncol 2021;11:672055. [PMID: 34168992 DOI: 10.3389/fonc.2021.672055] [Reference Citation Analysis]
311 Di Costanzo GG, Signoriello S, Tortora R, Gallo C. A prognostic index for patients within the intermediate stage of hepatocellular carcinoma: . European Journal of Gastroenterology & Hepatology 2016;28:592-8. [DOI: 10.1097/meg.0000000000000562] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
312 Shakado S, Sakisaka S, Okanoue T, Chayama K, Izumi N, Toyoda J, Tanaka E, Ido A, Takehara T, Yoshioka K, Hiasa Y, Nomura H, Seike M, Ueno Y, Kumada H. Interleukin 28B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis C virus-related liver cirrhosis: A multicenter retrospective study in Japan. Hepatol Res 2014;44:983-92. [PMID: 24400682 DOI: 10.1111/hepr.12280] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
313 Worland T, Harrison B, Delmenico L, Dowling D. Hepatocellular Carcinoma Screening Utilising Serum Alpha-Fetoprotein Measurement and Abdominal Ultrasound Is More Effective than Ultrasound Alone in Patients with Non-viral Cirrhosis. J Gastrointest Cancer 2018;49:476-80. [PMID: 28920172 DOI: 10.1007/s12029-017-0006-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
314 Dotters-Katz SK, Kuller JA, Hughes BL; Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org. Society for Maternal-Fetal Medicine Consult Series #56: Hepatitis C in pregnancy-updated guidelines: Replaces Consult Number 43, November 2017. Am J Obstet Gynecol 2021;225:B8-B18. [PMID: 34116035 DOI: 10.1016/j.ajog.2021.06.008] [Reference Citation Analysis]
315 Guo C, Zhou S, Yi W, Yang P, Li O, Liu J, Peng C. Long non-coding RNA muskelin 1 antisense RNA (MKLN1-AS) is a potential diagnostic and prognostic biomarker and therapeutic target for hepatocellular carcinoma. Exp Mol Pathol 2021;120:104638. [PMID: 33878313 DOI: 10.1016/j.yexmp.2021.104638] [Reference Citation Analysis]
316 Ferrante SA, Chhatwal J, Brass CA, El Khoury AC, Poordad F, Bronowicki JP, Elbasha EH. Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infect Dis 2013;13:190. [PMID: 23621902 DOI: 10.1186/1471-2334-13-190] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
317 Naugler WE, Sonnenberg A. Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma. Liver Transpl 2010;16:1186-94. [PMID: 20879017 DOI: 10.1002/lt.22129] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 4.2] [Reference Citation Analysis]
318 Riaz MN, Faheem M, Anwar MA, Raheel U, Badshah Y, Akhtar H, Tamanna K, Tahir M, Sadaf Zaidi NU, Qadri I. PCR-Based Molecular Diagnosis of Hepatitis Virus (HBV and HDV) in HCV Infected Patients and Their Biochemical Study. J Pathog 2016;2016:3219793. [PMID: 27366331 DOI: 10.1155/2016/3219793] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
319 Nwankwo C, Corman SL, Elbasha EH. Projected impact of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 and chronic kidney disease in Vietnam. J Infect Public Health 2019;12:502-8. [PMID: 30711348 DOI: 10.1016/j.jiph.2019.01.054] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
320 Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver Int. 2016;36:936-948. [PMID: 26972930 DOI: 10.1111/liv.13115] [Cited by in Crossref: 69] [Cited by in F6Publishing: 51] [Article Influence: 13.8] [Reference Citation Analysis]
321 Giannini EG, Marabotto E, Savarino V, Trevisani F, di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F. Hepatocellular carcinoma in patients with cryptogenic cirrhosis. Clin Gastroenterol Hepatol. 2009;7:580-585. [PMID: 19418607 DOI: 10.1016/j.cgh.2009.01.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
322 Famularo S, Donadon M, Cipriani F, Ardito F, Carissimi F, Perri P, Iaria M, Dominioni T, Zanello M, Conci S, Molfino S, LaBarba G, Ferrari C, Germani P, Patauner S, Pinotti E, Lodo E, Garatti M, Sciannamea I, Troci A, Conticchio M, Floridi A, Chiarelli M, Fumagalli L, Memeo R, Crespi M, Antonucci A, Zimmitti G, Zanus G, Zago M, Frena A, Tarchi P, Griseri G, Ercolani G, Baiocchi GL, Ruzzenente A, Jovine E, Maestri M, DallaValle R, Grazi GL, Giuliante F, Aldrighetti L, Torzilli G, Romano F;  HE. RC.O.LE.S. Group. Hepatocellular carcinoma surgical and oncological trends in a national multicentric population: the HERCOLES experience. Updates Surg. 2020;72:399-411. [PMID: 32170630 DOI: 10.1007/s13304-020-00733-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
323 Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol. 2009;50:1142-1154. [PMID: 19395111 DOI: 10.1016/j.jhep.2009.01.019] [Cited by in Crossref: 148] [Cited by in F6Publishing: 143] [Article Influence: 12.3] [Reference Citation Analysis]
324 Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B, Berger BD, O'Connor JK, Goldstein RM. Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent). 2008;21:266-280. [PMID: 18628926 DOI: 10.1080/08998280.2008.11928410] [Cited by in Crossref: 105] [Cited by in F6Publishing: 97] [Article Influence: 10.5] [Reference Citation Analysis]
325 Romano A, Angeli P, Piovesan S, Noventa F, Anastassopoulos G, Chemello L, Cavalletto L, Gambato M, Russo FP, Burra P, Vincenzi V, Scotton PG, Panese S, Tempesta D, Bertin T, Carrara M, Carlotto A, Capra F, Carolo G, Scroccaro G, Alberti A. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study. J Hepatol. 2018;69:345-352. [PMID: 29551707 DOI: 10.1016/j.jhep.2018.03.009] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 22.0] [Reference Citation Analysis]
326 Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014;61:S58-68. [PMID: 25443346 DOI: 10.1016/j.jhep.2014.07.012] [Cited by in Crossref: 449] [Cited by in F6Publishing: 399] [Article Influence: 64.1] [Reference Citation Analysis]
327 Purcell Y, Copin P, Paulatto L, Pommier R, Vilgrain V, Ronot M. Hepatocellular carcinoma surveillance: Eastern and Western perspectives. Ultrasonography 2019;38:191-9. [PMID: 30690962 DOI: 10.14366/usg.18043] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
328 Forner A, Reig M, Bruix J. Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star. Gastroenterology. 2009;137:26-29. [PMID: 19482098 DOI: 10.1053/j.gastro.2009.05.014] [Cited by in Crossref: 64] [Cited by in F6Publishing: 50] [Article Influence: 5.3] [Reference Citation Analysis]
329 Viganò M, Degasperi E, Aghemo A, Lampertico P, Colombo M. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opinion on Biological Therapy 2012;12:193-207. [DOI: 10.1517/14712598.2012.646986] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 6.2] [Reference Citation Analysis]
330 Rustgi VK, Davis GL, Herrine SK, Mccullough AJ, Friedman SL, Gores GJ. Future trends in hepatology: Challenges and opportunities. Hepatology 2008;48:655-61. [DOI: 10.1002/hep.22451] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
331 Corman S, Elbasha EH, Michalopoulos SN, Nwankwo C. Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection. Value in Health 2017;20:1110-20. [DOI: 10.1016/j.jval.2017.05.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
332 Bruno S, Boccaccio V, Russo ML, Maisonneuve P. Is the benefit of treating patients with cirrhosis proven? Liver Int. 2016;36 Suppl 1:21-27. [PMID: 26725893 DOI: 10.1111/liv.13013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
333 Giannini EG, Trevisani F. Ramucirumab as a second-line treatment for hepatocellular carcinoma: reaching out further to patients with elevated alpha-fetoprotein. Hepatobiliary Surg Nutr 2019;8:515-8. [PMID: 31673543 DOI: 10.21037/hbsn.2019.04.19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
334 Cabrera R, Pannu DS, Caridi J, Firpi RJ, Soldevila-Pico C, Morelli G, Clark V, Suman A, George TJ Jr, Nelson DR. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment Pharmacol Ther 2011;34:205-13. [PMID: 21605146 DOI: 10.1111/j.1365-2036.2011.04697.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 75] [Article Influence: 6.7] [Reference Citation Analysis]
335 Luo X, Wang Y, Shen A, Deng H, Ye M. Relationship between the rs2596542 polymorphism in the MICA gene promoter and HBV/HCV infection-induced hepatocellular carcinoma: a meta-analysis. BMC Med Genet 2019;20:142. [PMID: 31419949 DOI: 10.1186/s12881-019-0871-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
336 Tanoue S, Chang LY, Li Y, Kaplan DE. Monocyte-derived dendritic cells from cirrhotic patients retain similar capacity for maturation/activation and antigen presentation as those from healthy subjects. Cell Immunol 2015;295:36-45. [PMID: 25734547 DOI: 10.1016/j.cellimm.2015.02.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
337 Forner A, Ayuso C, Isabel Real M, Sastre J, Robles R, Sangro B, Varela M, de la Mata M, Buti M, Martí-Bonmatí L, Bru C, Tabernero J, Llovet JM, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma]. Med Clin (Barc) 2009;132:272-87. [PMID: 19248879 DOI: 10.1016/j.medcli.2008.11.024] [Cited by in Crossref: 56] [Cited by in F6Publishing: 35] [Article Influence: 4.7] [Reference Citation Analysis]
338 Ripoll C, Groszmann RJ, Garcia-Tsao G, Bosch J, Grace N, Burroughs A, Planas R, Escorsell A, Garcia-Pagan JC, Makuch R, Patch D, Matloff DS; Portal Hypertension Collaborative Group. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol. 2009;50:923-928. [PMID: 19303163 DOI: 10.1016/j.jhep.2009.01.014] [Cited by in Crossref: 228] [Cited by in F6Publishing: 180] [Article Influence: 19.0] [Reference Citation Analysis]
339 Galani BR, Sahuc ME, Njayou FN, Deloison G, Mkounga P, Feudjou WF, Brodin P, Rouillé Y, Nkengfack AE, Moundipa PF, Séron K. Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro. Front Microbiol 2015;6:488. [PMID: 26029203 DOI: 10.3389/fmicb.2015.00488] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
340 Krampitz GW, Aloia TA. Staging of Biliary and Primary Liver Tumors. Surgical Oncology Clinics of North America 2019;28:663-83. [DOI: 10.1016/j.soc.2019.06.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
341 Ghany MG, Morgan TR;  AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020;71:686-721. [PMID: 31816111 DOI: 10.1002/hep.31060] [Cited by in Crossref: 145] [Cited by in F6Publishing: 110] [Article Influence: 145.0] [Reference Citation Analysis]
342 Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-370. [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9] [Cited by in Crossref: 661] [Cited by in F6Publishing: 588] [Article Influence: 165.3] [Reference Citation Analysis]
343 . Guideline 2: Treatment of HCV infection in patients with CKD. Kidney International 2008;73:S20-45. [DOI: 10.1038/ki.2008.85] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]